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Abstract
Alzheimer’s disease (AD) has recently been labelled the ‘twenty-first century plaque’ and it
has been estimated that more than 40 million people around the world suffer from this
progressive disease. Within the amyloid hypothesis in Alzheimer’s disease, current focus has
shifted to earlier stages of amyloid beta (Aβ) peptide assembly, involving soluble oligomers
and smaller aggregates that are more toxic to cells compared to their morphological distinct
fibril forms. Critical to the Aβ field is unlocking the molecular-level kinetic pathways or
mechanisms of oligomerization, leading to the culprit subset or specific species of Aβ oligomer
populations responsible for the disease etiology. However, since the protein aggregation is
highly dynamic, involving temporally and kinetically controlled processes, and also very
difficult to monitor in the early stages, a key challenge is understanding dynamic Aβ at the
single molecule level under physiologically relevant conditions such as liquid.

Therefore, to probe the combined structural-dynamics of Aβ peptides, High-Speed
Atomic Force Microscope (HS-AFM) was used, as it enables direct observation of single
molecules at sub-molecular spatial resolution and with time resolution of up to 50milliseconds.
For example, the main inventors of HS-AFM, Toshio Ando and his co-workers, produced realtime videos of the walking mechanism of a single Myosin V along an actin filament. Such
movies existed before only as animations, but have now become reality due to the advent of
HS-AFM. The thesis comprises 5 chapters, including introduction, 3 experimental and
conclusion/future work.

In Chapter 1, we introduce and provide background to Alzheimer's disease and the
evolution of hypothesis explaining the disease pathogenesis, including current hypothesis
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focusing on the role of amyloid fibrils versus oligomers. This is followed by descriptions of
the mechanisms and kinetics underlying the nucleation and growth of amyloid fibrils and
oligomers, and a brief overview of current and treatments and therapies in Alzheimer's disease.
Finally, we highlight current approaches for molecular level characterization of amyloid and
its importance in understanding the disease.

In chapter 2, the molecular structures and dynamic diffusion of Aβ42 peptides were
characterized using HS-AFM and corresponding classification based on their structural
dimensions demonstrated the presence of oligomer and larger aggregate species. In addition,
based on HS-AFM movies, an analysis method was developed to quantify the kinetic
parameters for interactions between the different Aβ species. The interactions between
oligomers occurred more frequently, with binding consisting of a single exponential decay of
lifetime at 0.55 ± 0.22s for Aβ15–20nm and 0.72 ±0.28s for Aβ36nm, respectively. In contrast, the
larger aggregates exhibited kinetic heterogeneity and could form long-lived, stable complexes.
Inevitably, the latter may lead to the formation of different complexes or alloforms, which is
known to contribute to difficulties in identifying Aβ oligomer toxicity and has implications for
mechanisms underlying neuronal death accompanying Alzheimer’s disease.
In chapter 3, the effect of different environmental factors such as peptide concentration,
solution pH and incubation time on the Aβ morphology, dimensions and dynamics were
investigated using samples prepared ex-situ. The effects of concentration and incubation time
were minimal, whereas a decrease in solution pH was found to significantly accelerate the
formation of intermediate aggregates. In-situ HS-AFM experiments involving changing the
solution pH, i.e. changing from neutral to acidic conditions, during imaging to directly observe
the real-time nucleation and growth of the Aβ oligomers and aggregates. A single molecule
analysis approach based on HS-AFM was applied to quantify rate determining kinetic constants
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of the different nucleating forms of Aβ. The findings revealed that assembly mechanisms of
newly formed and existing peptides exhibited separate pathways during the nucleation
processes.

In chapter 4, having characterized the morphology and dynamics of the Aβ peptides, their
interactions with nanoparticles were investigated on the basis that the use of nanomaterials is
an emerging approach to control the aggregation process, or even sequester the toxic species.
Thus, as a model system, the dynamics and structural analysis of silica nanoparticles were
characterized followed by a co-deposition with Aβ peptides to investigate silica nanoparticleAβ peptide interactions. Kinetic analysis showed that an increase in nanoparticle size caused a
significant decrease in diffusion, which in turn led to an increase binding lifetime. The
implications for the effect of nanoparticle size and diffusion on the kinetic analysis are
discussed. Finally, Chapter 5 provides conclusions together with recommended directions for
future work.
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Chapter 1: Introduction
1.1 Neurodegenerative and Alzheimer’s disease
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and
Huntington’s disease are major threats to human health and welfare in the modern world [1-5].
Aberrant folding and abnormal accumulation of proteins in the brain are increasingly being
realised as the major pathological hallmarks of these neurodegenerative disorders [6, 7].
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disorder that
destroys people’s memory, reduces their ability to perform daily activities and even affects
their personality. It represents the most common progressive disease and is the leading cause
of dementia in the elderly, currently affecting more than 40 million people around the world
[8]. It was first identified by Dr. Alois Alzheimer more than 100 years ago, with common
clinical symptoms including memory loss and cognitive and functional abilities decline that
are believed to contribute to the cause of death in AD.

1.2 Pathogenic Hallmarks of AD
1.2.1 Senile plaques and neurofibrillary tangles
In AD, the accumulation of amyloid-beta (Aβ) peptide outside of neurons is believed to
contribute to the formation of senile plaques and accumulation of unusual protein tau inside
neurons, referred as the tangles. These protein structures were first observed in 1901 by Dr.
Alois Alzheimer who detected neurofibrillary tangles and senile plaques in the brain of a
patient by using the silver impregnation method [9-13]. However, it was only after the late
1960s when newly emerging tools of research, i.e. electron microscopy (EM), were developed
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that the observation of these proteins in the brain of patients with AD started to progress further.
For example, Kidd et al. [14] visualized the ultrastructure of neurofibrillary tangles formed by
paired helical filaments in 1963 and Terry et al. [15, 16] captured the senile plaques with a core
of amyloid fibrils in 1964 as shown in Figure 1. 1. Quantitative measurements regarding the
relationship between the degree of dementia and the number of plaques or tangles in each
cortex were also examined by comparing the brains of diseased and healthy patients in vivo
[17, 18]. These early studies provided a clear identification for the two abnormal proteins (Aβ
and tau) and basis for the development of the molecular pathogenesis of AD. The brain changes
associated with AD mentioned above significantly affect the communication between neurons
and lead to the neuron cell death [19-21]. In these cases, eventually, the brains of people with
advanced AD dramatically shrink due to the cell loss and corresponding synaptic loss, which
is believed associating with the toxic species of Aβ peptide.
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Figure 1. 1. Ultrastructure of neurofibrillary tangles formed by paired helical filaments. (A) Longitudinal sections
of filaments.1.5 ㎛*1.0 ㎛ (B) filaments cut in cross section.3.75 ㎛*2.50 ㎛ [15].

Together with the emerging role of the cholinergic system (i.e. neurotransmitter
acetylcholine signalling in neurons) in memory and learning, the first cholinergic hypothesis
of AD was established more than thirty years ago according to findings of a strong correlation
between cholinergic abnormalities and the numbers of plaques and tangles [22-26]. According
to this hypothesis, the cognitive dysfunction behaviour related to AD is attributed to the decline
in cholinergic neurotransmission [27], which indicated that drugs like cholinesterase inhibitors
could potentially be used for treatment against the disease, however, the therapeutic treatments
were proven to only be able to relieve temporary symptoms in AD [28-31].
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Since these early observations, the field has largely been built on a few main hypothesis.
Over the years, the amyloid cascade hypothesis has been pursued extensively though this has
been more recently challenged by the hypothesis involving soluble Aβ protein assemblies such
as Aβ-derived diffusible ligands (ADDL’s) [32, 33].

1.2.2 Aβ cascade hypothesis
Progress in the diagnosis of AD during the last 30 years has culminated in the amyloid-cascade
hypothesis that describes the etiologic and pathogenic mechanisms of AD. This hypothesis is
explained by the excessive deposition of Aβ peptides in the form of extracellular plaques, as
well as neurofibrillary tangles in the brain. To initially produce the abhorrent Aβ peptide, the
modification of the Aβ precursor protein (APP) is thought to occur via 2 pathways (Figure 1.
2) [34]. In the first pathway, the APP is cleaved by β-secretase and then followed by γ-secretase
cleavage though this pathway does not result in formation of amyloid. Alternatively, cleavage
by lysozyme in the endosomal-lysosomal compartment results in formation of Aβ peptide that
is believed to accumulate to form the amyloid plaques and tangles.

Figure 1. 2 Early amyloid cascade hypothesis. The APP produced mainly via 2 ways: (i) APP is first cleaved at
residues 15-17 by the APP ‘secretase’. This cleavage event produces fragments that can not form to amyloid
deposition. (ii) Several studies suggested that APP can also processed by the endosomal- lysosomal pathway, in
which the entire AβP sequence and in further the amyloid deposition are formed. Eventually these deposition lead
to the neurofibrillary tangles and cell death [34].
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Amyloid beta peptide (Aβ) comprises 39–43 amino acids and amyloid fibrils are the
dominant structures in senile plaques (SPs). The fibrils and plaques can physiologically induce
the neurotoxicity directly, or indirectly by the formation of neurofibrillary tangles (NFTs),
resulting in the formation of intracellular paired helical filaments (PHFs) and ultimately
neuronal cell death. A growing number of genetic studies revealed that the identified mutants
are highly correlated with the increased formation of total Aβ or fibrils. Specifically, the
fibrillogenic Aβ42, a 42 amino acid proteolytic product from APP, is postulated as the main
component in the pathogenic process, leading to the formation of insoluble oligomers or fibrils.
(Figure 1. 3)

Figure 1. 3. TEM (Transmission Electron Microscopy) and AFM (Atomic Force Microscopy) images of
oligomeric and fibrillar Aβ40, Aβ42. TEM images of Aβ40, Aβ42 fibrils were acquired through prolonged incubation
in PBS under stagnant conditions. Scale bar is 200nm. AFM Images were recorded in 2 μm*2 μm contact mode
with oligomers formed in Tris-buffered saline (TBS) after 24 h and tapping mode with fibrils formed in 10 mM
HCl after 24h [35, 36].
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In recent times, the amyloid cascade hypothesis has been debated on several aspects,
largely concerning the implication that Aβ oligomers and other pre-fibrillary assemblies, and
not the plaques and tangles per se, are primarily responsible for AD. The caveats for the
amyloid cascade hypotheses include the 1) lack of correlation between neurofibrillary amyloid
burden and neuronal dysfunction [37], 2) neurotoxicity of soluble Aβ peptide assemblies can
also explain an amyloid plaque-independent pathology [38], 3) oligomer-induced functional
memory loss that occurs before the neuronal death, and 4) concentration of soluble Aβ
oligomers in the brain plasma as opposed to the concentration of fibrils [39]. Over time these
observations have led to renewed suggestions that soluble Aβ oligomers and pre-fibrillary
assemblies, rather than mature fibril deposits comprised in plaques, hold the clues to
understanding the mechanisms of neurotoxicity in AD [39-45]. Several studies have since
confirmed that Aβ oligomers are potent neurotoxins [45-47]. Aβ pre-fibrillary assemblies are
also associated with many other protein-misfolding diseases like Parkinson’s disease,
Huntington's disease and Systemic Amyloidosis [41, 48, 49].

1.2.3 ADDL’s hypothesis
Increasing evidence suggested that oligomeric and pre-fibrillary structures are key neurotoxic
effectors in AD [38, 46, 50-53]. The complexity of their Aβ assembly is apparent due the
existence of several prototypes, forms and structures. Studies have confirmed various Aβ
assemblies (Figure 1. 4), each given their own terminology, including monomeric Aβ
conformers [54], oligomers [46, 53, 55-58], ADDLs [59], protofibrils (PF) [60, 61], Aβ*56
[62], paranuclei [63-65], amylospheroids [66] , annular assemblies [67], amyloid pores [46, 67,
68], and Aβ balls [69]. Owing to this diversity and complexity, elucidating their relevance to
AD pathogenesis remains a challenge. Nevertheless, a growing number of studies
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demonstrating their toxicity has seemingly caused a shift towards developing therapeutic
strategies based on these pre-fibrillary Aβ assemblies. Henceforth, the longstanding hypothesis
that amyloid fibrils are considered as the only active molecular pathogen has given way to a
new paradigm associating with small toxins and we use the term ADDL to describe these small
soluble oligomeric structural Aβ aggregates.

Figure 1. 4. Different Aβ42 assemblies. (A) TEM images of Amylospheroids formed in Aβ 42 solution (0.1 μM in50%
PBS) after an 8h slow rotation, scale bar 20nm. (B) AFM images of Aβ42 annular structured assemblies, the inset
represents a 50*50nm topography image of annular assemblies. (C) AFM image of toxic globular oligomers of
Aβ42 (ADDLs) [32, 70, 71].

In 1995 Oda et al. [72] proposed that soluble aggregated Aβ complexes rather than Aβ
fibrils were the molecular pathogens of AD. They demonstrated that the complexes of Aβ42
formed in the presence of clusterin have a significant suppression effect on the Aβ aggregation
and surprising enhancement of the neurotoxicity [73, 74]. Subsequent studies on the neurotoxic
effect of ADDLs in synaptic loss and associated memory dysfunction, particularly the action
in the neural signal transduction pathway, as well as cultured hippocampal neurons were first
described by Lambert et al. [46, 75]. In addition, ADDLs were also found to be responsible for
the long-term potentiation (LTP) inhibition and consequential neurological dysfunction, which
was believed to directly cause the memory loss of AD [76-78]. Characterization of ADDL’s in
both in-vitro and in-vivo studies have not only revealed the detailed biological structure of these
toxic oligomers but also provided a fundamental basis for understanding their role in AD,
which is schematically outlined in Figure 1. 5 [38, 46, 59, 76, 79-83]. Although ADDLs have
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been defined as a neurotoxic subset of Aβ42 oligomers, knowledge of their precise structure
and definitive conclusion on their cytotoxic assemblies is still limited.

Figure 1. 5. Diagram of ADDLs hypothesis shows all the elements involved with AD [79].

As such, although Aβ is commonly believed to be a causative factor in AD, the role of
mature fibrils and non-fibrillar structural Aβ species in the pathogenesis of AD remains unclear.
Recently, however, in vivo studies demonstrated that these oligomeric species of Aβ42 are
highly correlated with the severity of neurodegeneration in AD while some in vitro studies also
confirmed the neurotoxicity of these non-fibrillar structures such as oligomers, ADDL’s and
proto-fibrils [84]. Karie et al. [85] reported that oligomers can inhibit neuronal viability 10
times more than mature fibrils and the toxicity increased 40-fold compared to non-aggregated
peptides, indicating oligomers are the active species of the Aβ peptide that ultimately cause the
synaptic loss and AD related degenerative disease.
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1.3 Pathways of Aβ assembly
1.3.1 Kinetics of oligomer and fibril formation
The mechanisms by which Aβ monomers aggregate to form oligomers and fibrils have been
extensively studied, as identifying the pathways leading to toxic species is viewed as critical
for targeting with therapies. One of the well-known pathways is called nucleation-dependent
polymerization reactions (shown in Figure 1. 6) [6]. In this reaction, a slow nucleation step
initially occurs, producing a ‘lag phase’ during assembly, followed by a rapid fibril elongation
step. To prove this transition, extensive X-ray diffraction and electron microscope studies have
shown that the end product consists of characteristic, β-sheet-rich fibrils [39]. However, the
polymerization processes revealed unexpected complexity in the numbers, types and structures
of these aggregates. For example, a defined ‘on-pathway’ assembly required self-assembly of
monomers into a nucleus, which is essential for the fibril elongation phase. On the other hand,
an ‘off-pathway’ during fibril formation is associated with formation of distinct structural
aggregates such as Annulus or Amylospheriod [86, 87] that represent globular assemblies.
Related studies have confirmed that these globular assemblies will not form fibrils but they do
have rich β-sheet structure content, which is believed to exist at the C terminus [88-90].
Compared to amylospheroids, which have spheroid structures with diameter around 15 nm,
amyloid balls are larger spheroid species formed only by Aβ40 at high concentrations (300–600
μM) [60]. It is believed that this high concentration of soluble Aβ might be associated with an
interesting model of amyloid plaques, which is discovered in some brain disorders like
Parkinson’s and Huntington diseases [57].
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Figure 1. 6. Schematic of the nucleation-dependent polymerization model of Aβ aggregation. It reveals two phases
are revealed during the amyloid aggregation: (i) the nucleation phase/lag phase, in which monomers undergo
conformational changes/misfolding and consequently form oligomeric nuclei, (ii) the elongation phase/ growth
phase, in which the nuclei rapidly grow by additional monomers to form larger aggregates or fibrils eventually
[6].

As mentioned above, peptides can form various structural and types of soluble
aggregates through the nucleation-dependent polymerization and one distinct feature of this
process is the lag time before these aggregates are detectable, in which the dimers, trimers and
eventually the nucleus (n-mers) will be formed [91]. However, this nucleation phase/lag phase
is thermodynamically unfavourable and processes step by step while the elongation
phase/growth phase is much more favourable and occurs quickly, which means the kinetic of
amyloid formation can be well represented by the sigmoidal curve with a lag phase followed
by the elongation phase (Figure 1. 6 green curve). In addition, the rate of formation of nuclei
will be significantly determined by the seed concentration and additional seeds/nuclei will
gradually increase the rate of aggregation by reducing the lag time (Figure 1. 6 red curve).
Although this lag time is extremely concentration dependent, the effects on the formation of
nucleus such as the structure, size of oligomers and the transition mechanisms are still not clear
35

[92-94]. A simple schematic example is shown in Figure 1. 7 to illustrate the general stages of
Aβ fibrillation.

Figure 1. 7. A simple scheme shows the kinetic curve for amyloid formation above barely the crucial concentration
CR [91].

1.3.2 Nucleation mechanisms of amyloid formation
Aβ aggregation is a complicated process, involving various structural conformation changes
and self-assembly of Aβ monomers to form rich β-sheet structural intermediates, protofibrils
and mature filaments [66]. During the early stage of Aβ aggregation, two important
microscopic steps involved in the nucleation-dependent polymerization are referred to as the
primary and secondary pathways [95-97]. The primary pathway, such as homogeneous
nucleation [95], is defined as a spontaneous process in which new soluble monomers can
associate into existing aggregates or fibrils at a rate only dependent on the concentration of
monomers (As shown in Figure 1. 8a, where kn is the nucleation rate constant, [m] is monomer
concentration and nC is represented as length of the smallest growth component fibril) and
subsequent addition of the monomers will eventually elongate the fibrils (As shown in Figure
1. 8b, where [f] is the fibril number concentration) [98]. The secondary pathway, where the
concentration of existing fibrils is the determining factor, can be classified into monomerdependent secondary nucleation and monomer-independent fragmentation (As shown in Figure
1. 8c and 8d, where [M] refers to the total fibril mass concentration) [99-102]. In the monomer36

dependent secondary nucleation, several monomers combine to form a fibril by the presence
of another fibril, the rate equation represented here is analogous to that for primary nucleation
while the [M] accounts for the fact that longer fibrils have more sites for the reaction. The
fragmentation is defined by the fibrils break into two separate shorter fibrils and the rate
equation is associated with fragmentation rate constant and individual fibril concentration.
Figure 1. 8 below show theses different kinetic pathways of amyloid fibril formation [103].

Figure 1. 8. Kinetics of different pathways underlying the amyloid formation. (a)Primary nucleation from
monomers, (b) Elongation by addition of monomers to existing aggregates. The secondary nucleation shows the
combination of both monomeric and aggregated species and finally the fibrils formed at fragmentation stage. (c)
Monomer-dependent secondary nucleation from monomers on surface of fibrils or aggregates. (d) monomerindependent fragmentation. All the monomers are coloured in green while the aggregates or fibrils are coloured
blue [103].

Determining the fundamental steps in the structural evolution of fibrils and associated
kinetics during these nucleation processes is important for therapeutic targets. Recently,
Cohen et al. [104] suggested that monitoring and control of the secondary nucleation pathway
during the Aβ aggregation is potentially an effective strategy to sequester the neurotoxic
oligomers. For example, depending on the monomer concentration, the rate of both oligomer
and fibril formation and the resulting cytotoxic effects can be directly detected by selective
radiolabelling methods and cell viability assays, which is shown in Figure 1. 9. In addition, a
critical concentration of Aβ fibrils determined the pathway or assembly mechanism of Aβ
aggregation is also emphasised in the study, suggesting a potential approach to target precisely
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certain structural species and control the amyloid pathways by adjusting the additional fibril
concentration. Lomakin et al. [105] also reported the concentration-dependence of fibril
elongation rate and the correlated fibril length from the quantitative analysis of different Aβ
nucleation stages including pre-nucleation, nucleation and elongation process by quasielastic
light scattering spectroscopy (QLS). The size of fibril nuclei and Aβ oligomers with
corresponding rate constant of formation for fibrils are also determined. Thus, the complexity
and diversity of factors influencing the nucleation of fibrils and kinetic parameters of growth
could be essentially solved by these proposed models and technical examination.

Figure 1. 9. Measurement of oligomers populations with radiolabling method and cell viability assays. (A)
Samples of monomers and monomers mixed with preformed fibrils were incubated followed by size-exclusion
chromatography and liquid scintillation counting. The numbers of oligomers fractions are shown below. (no fibrils
for light blue bar and added fibrils for dark blue bar ) (B)Probing the chromatography fractions with antibodies
further confirms the enhanced production of small oligomers in the presence of fibril. Time Δt1=24mins.
(C)Measurement of reduced cell viability for reactions without (light blue bars) and with (dark blue bars) a small
concentration of added fibrils under the same conditions as in A and after filtration through a 200-nm filter. Values
are averages over nine measurements at Δt2 =5, 6, 7 mins. Grey bars represent initial monomers and end fibrils
reaction time points.(D) Comparason of kinetic measurement between two conditions. The rapid increase in the
slope with added fibrils (dark blue) and consequent shorter lag time suggest the rapid formation of new aggregates
through secondray nucleation [104].
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1.3.3 Effect of Aβ state on the pathway of aggregation
The multiplicity of Aβ state, in which the polypeptide chains adopted to form a well-defined
structure, can be generally classified into native state with functional structures, misfolded state
with disordered or partially ordered conformations and various structural intermediate
aggregates. Proteins can biologically adopt various other conformation states in addition to the
native structure. Tuomas P.J. Knowles and his co-workers demonstrated the amyloid state and
its association with protein misfolding disease [106]. For example (as shown in Figure 1. 10),
particularly for those large or folded proteins functioning in native state, they can adopt
intermediate conformations before becoming fully folded. In addition, some partially folded
proteins may also adopt misfolded structures or aggregates, which is essential for specific
functional reasons such as the intracellular translocation requirements. Therefore, it was
proposed that formation of amyloid structures is not only associated with a small number of
diseases, but also that it suggests that the typical form of molecular structure should be related
to its functional state or the stages where they will be adopted [107]. To fully elucidate the
details on the relationship between Aβ states and their corresponding preferred protein
structures, it is important to characterize the nature and properties of different Aβ states in
which these particular structural molecules can be found [7, 107]. From another point of view,
the study on the amyloid state can also provide unique insights into the nature of the functional
forms of peptides and proteins, as well as understanding the conversion and the manner in
which the peptides tend to aggregate or maintain the specific state [108-110].
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Figure 1. 10. Amyloid state and its relationship with the structure and conformation of the proteins. The amyloid
structure is highly affected by the amyloid state. It is believed that peptides or some large fragments are natively
unfolded structure and eventually formed amyloid fibrils that are rich in β‑ sheet structure. During the whole
aggregation process, the different states corresponds to various structures [106].

Amyloid structures have different features from the native conformation, in which the
property of kinetic and thermodynamic stability will become a key factor to determine [111,
112]. It has been recognized that measurements of kinetics and thermodynamics are
fundamentally important not only for analysing experimental measurements in terms of
reaction mechanisms but also for predicting aggregation behaviour under conditions in which
such parameters cannot be measured [113]. While thermodynamics of various amyloid states
describes whether or not a transition from one state to another is spontaneous, the analysis of
kinetics will mainly emphasize how fast a transition could take place [113, 114].
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1.3.4 Effects of environmental conditions
Kinetic processes of amyloid aggregation are not only dependent on the concentrations of the
protein but also associated with some other factors such as the temperature, incubation time,
metal ions or liquid pH. For example, Kusumoto et al. showed that the fibril elongation rate
constant (Ke) is increased significantly by two orders of magnitude as the temperature increases
from 4℃ to 40℃. This temperature dependent Ke follows the Arrhenius equation:
Ke=Aexp(−EA/kT), where A is the pre-exponential factor, EA is the activation energy for the
reaction and T is the absolute temperature, resulting in higher activation energy and indicating
a possible conformational transition activity (Figure 1. 11) [115]. Ann Tiiman et al. [116]
similarly reported that fibril formation is accelerated at higher temperature and lag time
decreased from 10℃ to 45℃, however, at lower temperatures (4℃) and at physiological pH
oligomers were formed, revealing the conditions suitable for the production of the oligomeric
neuro-toxic species in AD [117-120].

Figure 1. 11. Arrhenius plot shows the temperature dependent fibril formation [115].

A growing number of studies revealed that the fibrillation process is independent of pH
in the range from 7 to 9, whereas the rate constant of fibril formation dramatically decreases at
lower pH, indicating an effect of protonation of histidine groups [121-123]. In acidic solution,
the protonated histidine will not be able to form salt bridge with aspartic acidic residues, as
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suggested in fibrillogenesis, rather the positively charged histidine will repel each other in the
structure of the forming fibrils, resulting the inhibition of the fibril formation. Further addition
of different mutants (H6A, H13A and H14A) were investigated to identify essential histidine
for the Aβ fibrillation and reveal inhibition mechanisms, which is shown in Figure 1. 12 [116].
It has been shown that the pH dependence of the fibrillation rate of H6A is similar to the wild
type Aβ42 while the fibrillation rate of H13A and H14A mutants are constant in the whole pH
range, suggesting that the protonation of H6A will not affect the fibril formation and both
histidine H13A and H14A inhibit the fibril formation. The pH dependency of Aβ aggregation
under acidic conditions sheds light on the peptide oligomerization and the corresponding
cytotoxicity issues of oligomeric Aβ. Yeu Su et al. [124] examined the structure and neurotoxic
effects of aggregates formed in different pH conditions and revealed that only aggregates that
formed at pH 5.8 induced a significant inhibition of 3-(4,5-dimethylthiazol-2-yl)2,5diphenyltetrazolium bromide (MTT) reduction, which is a colorimetric assay for assessing cell
metabolic activity, resulting in the death of PC12 cells (Figure 1. 13). Additional results from
a reliable neuronal cells detecting assay, annexin-V staining assay, further confirmed that the
aggregates formed at pH 5.8 contributed to the apoptosis of PC12 cells. These findings, along
with many current in vitro studies have been done in accordance with the finding that cell
organelles are filled with acidic components of senile plaques in the brain of patients with AD
[125].
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Figure 1. 12. The effect of pH on the fibril formation of Aβ 42, as a function of rate constant of fibril formation.
The aggregation of 5 µM wild-type (•), H6A (⸰), H13A (⸰) or H14A (∆) mutant of Aβ42 in 20mM ammonium
acetate, 100mM NaCl with continuous agitation in the presence of 3.3 µM ThT at 25℃ at different pH values
[116].

Figure 1. 13. Effects of pH 5.8 and pH 7.4 Aβ42 aggregates on the viability of PC12 cells. Aliquots from pH 7.4(▴)
or pH 5.8(•)Aβ42 aggregates or the non-aggregates (⸰) were incubated with PC12 cells for 48h and the cell
viability assay was conducted by MTT inhibition method [124].

Fundamental knowledge of the Aβ42 assembly process in terms of comprehension of
both the kinetics and mechanisms of the Aβ42 aggregation, combined with the understanding
of popular pathways and various effectors in the progress. It is realizable to maintain the
specific structural protein species by regulating the protein concentrations at different
aggregation phases and by controlling the rates of the conversion between them. This will be
highly meaningful for various strategies proposed to suppress the production of the toxic
oligomeric species [126-129]. Therefore, the controllable process between different
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aggregation stages can be achieved by either disrupting the process of their formation or
promoting the pathways of their moving [130, 131]. The development of drugs that reduce the
risk of aggregation by decreasing the concentration and formation rates of the toxic protein
species has been an area of interest in recent times. Herein, an overview of the treatments and
strategies involved are presented below.

1.4 Current treatments and clinical therapies
1.4.1 Cholinesterase inhibitor treatments
The neuropathology of AD is characterized by early cholinergic neuronal loss, resulting in
decreased cholinergic transmission [132, 133]. Therefore, various cholinesterase inhibitors
have been introduced firstly by delaying the breakdown of acetylcholine, which is important
for the nerve cell communication and memory neurotransmission [134]. In addition, a recently
developed drug, Memantine, belonging to the N-methyl-d-aspartate (NMDA) receptor (and
one of the three types of ionotropic glutamate receptors), is shown to be capable of blocking
excess glutamate that can damage or kill nerve cells [135]. However, these treatments can only
provide symptomatic relief or delays in the progression state and cannot reverse the course of
the disease.
In addition to the Memantine mentioned above, at present only four cholinesterase
inhibitors (CheIs), Tacrine, Donepezil, Rivastigmine, and Galantamine are recognized and
approved by the U.S. Food and Drug Administration for treatment of AD [136]. Depending on
the different stage of the disease, these drugs all exhibit reasonable neuroprotective activity
and work by blocking the enzyme acetylcholinesterase so that the levels of acetylcholine in the
synaptic cleft can be maintained or elevated. Table 1. 1 [137] provides a brief summary of these
drugs. The success in symptomatic treatments led to the alternative development of functional
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drugs. For example, Phenserine, an inhibitor of acetylcholinesterase and capable of improving
cognitive function in dogs and rodents, was clinically tested in AD patients and showed
successful results to attenuate the progression of AD [138]. Other therapeutic targets such as
M1 muscarinic receptor agonists AF102B, AF150(S) and AF267B have also been investigated
and reported as cognitive enhancers with potential to modify AD [139, 140]. The effect of
nicotinic receptor agonists on cognitive functions of AD patients have also been investigated
for many years and currently most of them are in preclinical stages [141, 142].
Table 1. 1. Current treatments and approved therapies available for AD [137].

1.4.2 Anti-amyloid therapies
1.4.2.1 Prevent Aβ aggregation
Although the pathology of AD and identification of toxic species from diverse Aβ structures,
forms and aggregates are still unclear, targeting the neurotoxic activity of Aβ oligomers has
provided a fundamental basis for the development of compounds and drugs that aim to
purposefully suppress the Aβ oligomerization [39].
Tramiprosate, a glycosaminoglycan (GAG), was developed as the first generation of
anti-amyloid aggregation drugs designed to interfere with soluble monomeric Aβ species,
maintaining it in non-fibril form, and thus preventing oligomerization and aggregation [143].
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Clinical trials of patients with mild to moderate AD demonstrated promising efficacy in the
treatment for cognitive function improvement and stabilization of neurologic deficits [144].
The beneficial effects of those anti-amyloid aggregations compounds have also attracted some
clinical investigation such as the longitudinal Volumetric Magnetic Resonance Imaging
(VMRI) measurements of the decreasing atrophic hippocampus in patients with mild to
moderate AD, revealing their significant capabilities of improvement for cognition [145].
However, due to the low bioavailability and the side effect of toxicity issue associated with the
tau aggregation, the development of tramiprosate still requires further clinical evaluation and
recently some related projects have been terminated [146]. Some other inhibitors of Aβ
aggregation such as scyllo-inositol and Epigallocatechin-3-gallate (EGCg) worked via a similar
mechanism to prevent and even disassociate aggregates by binding to initially forming Aβ
species. These drugs were well tolerated and showed significant benefits in clinical trials [147,
148].

1.4.2.2 Promote Aβ clearance
An alternative approach to therapy in AD is to directly reduce the levels of Aβ in the brain,
which can be theoretically manipulated or balanced by the levels of Aβ degrading enzymes.
Therefore, many small molecule activators that function to ultimately reduce the Aβ levels
have been investigated. For example, the inhibitors of plasminogen activator inhibitor-1 have
proven to increase the Aβ catabolism and may constitute a reliable therapeutic approach to
lower the levels of Aβ in brain [149]. Recently, neprilysin was also implicated as a promising
Aβ degrading enzyme target since it can significantly reduce the levels of Aβ deposits in
transgenic mouse models [150]. However, further evaluation of these compounds and
characterization of the delivery approaches are poorly understood and require further testing.
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1.4.3 Metal ions
Accumulating evidence shows that transition metal ions and generated oxidative stress are
involved in the pathogenesis of AD [151-154]. In vitro studies indicate that physiological
concentrations of zinc and copper can accelerate Aβ aggregation and increase Aβ toxicity [155157]. As shown in Figure 1. 14a and 14b, the analysis of fibril growth kinetics, metal-free Aβ
preparation takes more than 70 ± 2 h to reach half maximal fluorescence while the fibril
formation time is nearly halved at 38 ± 2 h for the same preparation with Cu2+ ions. The
increased cytotoxicity induced by copper ions was also emphasized in Figure 1. 14c. The
concentration of iron in the brain of AD patients is also elevated [158]. Aβ peptide has a strong
positive reduction potential and displays high-affinity binding for Zn2+, Cu2+ and Fe3+ ions
[159]. Therefore, various metal chelating agents are potentially effective in attenuating the
effects of Aβ. PBT-2, one of the analogues of 8-hydroxyquinoline, has distinct chelating
properties, with good blood brain barrier (BBB) permeability, and widely used to inhibit zinc
and copper ions from binding to Aβ to accelerate clearance of Aβ oligomers. Subsequent
clinical trials with PBT-2 also confirmed its improvement in the memory and cognition in AD
animal models though further clarification of the safety, tolerability and efficacy are still
needed [160, 161]. Another metal ion-based system, Met35, participates in redox reactions and
has potential to modulate oxidative stress. Hou et al. [162] have reported that oxidation of
Met35 to Met35(O) significantly reduces the rate of amyloid formation and alters fibril
morphology. Bitan and Teplow [55] reported similar findings when Met35(O) Aβ42 does not
form pentamer/hexamer (paranuclei) which self-associate to form larger oligomers, but rather
oligomerizes similarly to Aβ40, indicating the role of Met35(O) in blocking the formation of
paranuclei and in controlling the pathway of Aβ oligomerization. However, the high affinity
property of these chelators may pose harmful effects when undesirable metal binding occurs in
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other tissues. Thus, an effective delivery approach for chelation combined with precise
targeting methods will provide significant therapeutic options for clinical treatment.

Figure 1. 14. Cu2+ accelerates Aβ growth and increases the cytotoxicity. (a) Average of 9 growth curves recorded
Apo in red and Cu2+ in blue. The fluorescence ThT signal is normalized at maximal intensity. Aβ 40 concentrated
at 5μM, HEPES buffer 50mM, 160mM NaCl at 30°C. (b) Time to reach half-maximal fluorescence (t50) in two
experiments with 0 (red), 1 (mid-blue) or 0.5 (dark blue) mole equivalents of Cu2+ ions. The presence of Cu2+
typically halves the time taken to form fibrils. Error bars are for standard from nine traces. (c) Cell viability
comparison [155].

1.4.4 Multi-target directed compounds
The complexity of pathology in AD has inspired researchers to develop multifunctional drugs
for various central nerve system (CNS) targets [163]. These multifunctional compounds will
interact via different mechanisms so that the specific benefits or symptomatic improvements
can be achieved [164]. For instance, a novel neuroprotective drug called TV3326 [(Npropargyl-(3R) aminoindan-5-y1)-ethyl methyl carbamate] possesses both cholinesterase and
monoamine oxidase inhibitory ability, thus can clinically increase the cholinergic
neurotransmission, levels of dopamine, serotonin and adrenaline in the brain, and provide
cognitive benefits [164]. TV3326 also has antioxidant properties and can modulate APP
processing and cellular signalling pathway, preventing cell death [165]. Similar acting
compounds of M-30 and Memoquin are also believed to be promising drugs for the anti-AD
[165, 166].
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Despite the symptomatic relief that has been achieved using the aforementioned
therapies and drugs in AD, which provided a promising basis for the development of clinical
treatments, in particular those targeting Aβ oligomerization and aggregation, unfortunately
none of them have made it successfully through clinical trials and approved for use at present.
One of the issues posed is that such drugs may be ineffective in treatment of patients diagnosed
with AD, as current diagnosis may represent late-stage or post-AD where the pathogenic
mechanisms of Aβ oligomerization and aggregation have already passed. In addition, another
challenge as mentioned is the current lack of understanding of ADDL’s in AD, particularly
their role in early stages and failure to identify which Aβ oligomers/aggregates are responsible
among their many diverse forms [167]. Alternatively, some emerging approaches to antibodies
or chemical compounds targeting Aβ oligomers will be further summarized below.

1.5 Alternative strategies
1.5.1 Nanoparticles (NPs)
Currently more than 98% of potential available drugs can’t transfer from blood to brain
effectively due to the physical barriers and BBB which is actually a cellular ‘fence’ to protect
brain from hazardous substances in the blood flow. For example, most of the current potential
iron chelators, as discussed above, are of relatively high molecular weight and are limited by
the poor transference across the BBB. Although modified lower molecular weight chelators
have shown a better ability to penetrate the BBB, the toxicity issue for the treatment of
chelation therapy are becoming serious [168, 169]. However, as the development of NPs
advanced in efficient drug delivery and improved drug targeting ability, nanoparticles
conjugated with metal ions are demonstrated as a new therapy option [170].

49

Beyond that, engineered NPs with size around 3-200nm and made of biocompatible
materials can be proposed to solve the problem of enhancing transport of drugs from blood to
brain [171]. Advancement in the encapsulation and surface modification of NPs also guarantee
the pharmaceuticals against degradation as well as increase their half-life time since most of
the NPs will be rapidly cleared by the reticuloendothelial system and mainly sequestered in
liver and spleen [172]. In order to make the particles suitable for BBB crossing to allow their
diffusion within the brain, it is also crucial to control the size of NPs below 200nm diameter
which is estimated as the largest pores present in extracellular spaces in the human brain tissue
[173]. Some functionalized NPs with potential drugs proposed for the treatment of AD are
listed below. (See Table 1.2)

Table 1. 2. Some NPs proposed for the treatment of Alzheimer’s disease [172].
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While there is a growing interest in the application on the NPs in biomedical field, many
issues remain to be considered, including the critical questions of the potential toxic effect of
NPs to human health. Current research data has only shown that NPs’ size, size distribution,
purity, shape, composition, surface coating, surface charge and surface reactivity result in a
different distribution, accumulation and transport of NPs to different organs, as well as across
the BBB [174-176]. It should be noted that most neurotoxicity studies performed so far have
focused on metal and carbon-based NPs. Thus it is difficult to apply a general rule regarding
brain toxicity of NPs and the benefits of NPs must be weighed against their potential toxic
effects. So far, in fact, the toxicity of NPs has not been fully understood and a complete
understanding of the molecular and pathogenic events of AD is also desired. However, drugloaded multi-functionalization NPs remain a viable option for the effective treatment of AD
[172, 177]. It should also be noted that the current nano-medicine treatments for AD therapy
are still limited to preclinical studies.

1.5.2 Nanomaterials
With the development of nanotechnology, and the emergence of a range of nanomaterials and
NPs for use in a variety of biomedical applications, the development of anti-AD therapies based
on nanotechnologies is seen as a promising avenue for investigation. For example, Zaixing
Yang et al. [178]revealed that graphene and graphene-oxide nano-sheets can significantly
inhibit Aβ peptide monomer fibrillation and extract a large number of peptides from preformed
amyloid fibrils. In this study, the results from AFM imaging studies showed that mature
amyloid fibrils can be disassociated into small pieces, further removed by graphene oxides, and
cell viability assays demonstrated that graphene oxide can significantly decrease the Aβ
cytotoxicity. These findings provided a fundamental basis for understanding the mechanisms
of graphene-Aβ protein interactions and Nano-therapies for AD [178].
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1.5.3 Photoexcitation Effects
Environmental factors play an important role in the progression of AD. Joon Seok Lee [179]
found that photo-excited Rose Bengal (RB) strongly inhibits Alzheimer’s Aβ42 aggregation
compared to RB exposed under dark conditions (Figure 1. 15). RB under green LED
illumination interfered with an early step in the pathway of Aβ42 self-assembly and inhibited
the conformation transition from monomers into toxic β-sheet-rich structure. Therefore,
utilizing photo-excited RB provide another potential strategy for effective suppression of Aβ
aggregation and cytotoxicity.

Figure 1. 15. Schematic illustration of the inhibition of Aβ aggregation by photo-excited RB [179].

1.5.4 Electrical Stimulation: A new paradigm for therapy
As we have witnessed, more electronic devices have been successfully developed in medical
area nowadays, especially in the bionics such as the bionic ear [180] , cardiac pacemakers [181]
and devices that provide electrical stimulation for bone regrowth [182]. Not only huge money
invested trying to find suitable drugs for treatment, but also people have to consider the sideeffect or toxicity of the conventional pharmaceuticals. Therefore, a new therapy that involving
deep brain stimulators for treatment of protein-aggregation disorders are potentially exciting
options in the future.
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Recently, Innocent Bekard et al. [183] and his group propose a model whereby the
electrophoretic motion of the proteins leads to a frictional force that results in protein unfolding
(Figure 1. 16). They measured the effect of a low strength oscillating electric field on the
conformation of Bovine serum albumin (BSA) and Lysozyme and confirmed that electric force
applied during electric field exposure was significant to perturb the tertiary structure of both
BSA and Lysozyme. They establish intrinsic protein fluorescence as a sensitive tool to study
the dynamics of the tertiary structure of native proteins in response to stress. Circular dichroism
is used to quantitatively explore the solution conformation of peptides and poly-peptides. In
addition, prolonged electric field exposure resulted in significant frictional energy dissipation
in the proteins. This observation that weak electric fields have the ability to dissipate energy in
proteins, and then result in the unfolding of the proteins, provides for potential health
implications.

Figure 1. 16. Schematic of the electro-cell. This purpose build cell is used to measure the real-time autofluorescence and circular dichroism of the protein solution exposed to electric fields of differing strength and
frequency [183].

1.6 Molecular characterization of Aβ
Unravelling the molecular structures of Aβ species and the process of amyloid aggregation are
thought of as two key aspects for revealing the molecular mechanisms of AD. In the following
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section, the different approaches used to characterize Aβ and their dynamic interactions are
summarized.

1.6.1 Structural measurements
Structural analysis of individual Aβ peptides, including aggregates, has been extensively
elucidated using techniques such as Fourier transform infrared (FTIR) spectroscopy, Circular
Dichroism (CD), Solid-state nuclear magnetic resonance (ss-NMR) spectroscopy and X-ray
crystallography [184, 185]. These methods will normally provide fundamental data regarding
the secondary structures of Aβ peptides and corresponding morphologies. For example, Liping
Yu et al. applied NMR to characterize the soluble Aβ oligomers and identified a mixed parallel
and antiparallel β-sheet structure in these soluble Aβ forms, which is different from the fibrils
that only contains β-sheet structure [186].

1.6.1.1 FTIR spectroscopy
FTIR has been widely used to detect the presence of β-sheet secondary structure, which is a
specific type of β-sheet fragment detected by X-ray diffraction (XRD) encompassed in the
amyloid fibrils [187]. This β-sheet secondary structure is detected by the presence of a band
near 1620cm-1 when examining the amide I region (1600-1700cm-1) of the spectrum of Aβ
fibril samples. Zandomeneghi et al. [188] distinguished amyloid fibrils and native β-sheet
proteins from the amide I region of their infrared spectra. They revealed a common group of
fibrillary structures, derived from various aggregates, which were distinct from the native βsheet proteins (Figure 1. 17). Moreover, this study suggested a potential therapeutic strategy
by inhibiting or disrupting the formation of structures associated with toxicity.
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Figure 1. 17. Structure of native protein transthyretin (TTR) and TTR amyloid fibrils.(A) Amide I region from
the FTIR spectrum of native TTR. (B) Ribbon diagram of native TTR tetramer.(C) Amide I region from the FTIR
spectrum of TTR fibrils. (D)Electron Microscopy (EM) images of TTR fibrils [188].

1.6.1.2 Atomic Force Microscopy (AFM)
Atomic Force Microscopy (AFM) has been widely applied to characterize the structures and to
distinguish soluble oligomeric Aβ peptides from highly aggregated fibrils. As shown in Figure
1. 18A, Hepler et al. [189]successfully captured the ADDLs in a globular structure with
approximately 3-5nm in height while the long strand accumulated fibrils were observed in
Figure 1. 18B. Interestingly in Figure 1. 18C, a highly magnified image of an isolated subunit,
which is referred as the globular oligomer, was observed next to a fibrillary strand that consist
of nine of these globular subunits arranged in a helically twisted bundle [189].
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Figure 1. 18. Atomic Force Microscopy images of standard prepared ADDLs (A), mature fibrils (B)and highly
magnified part of the fibrils along with an ADDL subunit (C). All the samples were imaged in air using tapping
mode [189].

More Recently, Iris A. Mastrangelo et al. [190] investigated the structure and formation
of these assemblies using AFM. By taking AFM images of various Aβ forms at early incubation
times (<1h), they revealed that the assembly from monomers, to soluble oligomers and protofibrils, subsequently with observations resulting in a stacking mode of assembly has been
proposed (Figure 1. 19). In this study, based on the molecular weight (MW) and associated
dimensions such as length, width and height, low MW oligomers consisted of two to four
monomeric units as shown in Figure 1. 19a, while the oligomers in Figure 1. 19b and 19c
appear to be twice as large as the structure in Figure 1. 19a. The proposed models presented
below in Figure 1. 19(d)-(f) are referred to the Aβ42 monomer, dimer and tetramer.

Figure 1. 19. (a)-(c) AFM images of Aβ42 peptides and (d)-(f) proposed models of the Aβ42 monomer, dimer and
tetramer [190]. Image scan size: 150 nm *150 nm

Furthermore, the unique capacity of AFM to provide high-resolution images of single
molecules over time has led to this technique becoming one of the main methods to follow the
dynamics of amyloid fibril formation. AFM imaging has shown that Aβ fibril formation is a
multistage process and indicates 4 main stages of assembly comprising diverse structures
including the 1) earliest proto-fibrils that exist in the form of unstructured Aβ monomers, 2)
subsequent proto-fibril elongation along with reversible disassociation, 3) proto-fibril to fibril
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transition, which is not a reversible stage and finally 4) fibril elongation [191]. Additionally,
the rate of elongation was dependent on the peptides concentration, temperature and ionic
strength of the medium in a comparable experiment. As the AFM images show below,
significant increases have been observed in the protofibril length with increasing incubation
time at 2 days, 7 days and 18 days (Figure 1. 20a), and increasing temperature at 3℃, 18℃ and
37℃ respectively (Figure 1. 20b). The statistical analysis further revealed a decrease in the
numbers of the protofibrils with the increasing time and temperature, indicating that
coalescence of smaller protofibrils contributes to the protofibril elongation. In addition,
statistical result of an averaged shorten length of protofibrils with the decreasing numbers in
diluted condition suggested an irreversible assembly progress [191].

(a)

(b)

Figure 1. 20. (a) AFM images of time dependence of Aβ 40 proto-fibril assembly at(scale bar:500nm*500nm) 2,
7 and 18 days. (b) AFM images show the temperature dependence of Aβ 40 proto-fibril assembly. Scale bar:
1000*1000nm [191].

The first in-situ AFM visualization, which means the fibrils formation is occurring
locally without isolating it from other systems, of proto-fibril formation from single aggregate
units of Aβ peptides that were 83.3 ± 18.2 nm wide with height at 4.5±2.8)nm was reported
by H.K.L Blackley et al. [192]. In addition to observing the growth of the proto-fibrils (Figure
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1. 21 (i)) and based on these findings, the authors proposed a mechanism for fibrillization of
Aβ (Figure 1. 21 (ii)). Importantly, this work demonstrated the possibility of observing the
binding of two single molecular aggregates during the early stages of proto-fibril formation
and understand the conditions that either activated or inhibited the aggregation processes [193].

(i)

(ii)

Figure 1. 21. (i) A series of AFM images depicting the development of multiple Aβ proto-fibril from a common
core. Imaging scan size 2.5um*2.5um.(ii) A schematic outlining a possible mechanism for the fibrillization of Aβ
[192].
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1.6.2 Fluorescence spectroscopy
1.6.2.1 Internal Reflection Fluorescence Microscopy (TIRFM)
In histological detection and microscopic observations, Congo red dye has been extensively
used for staining in amyloidosis. However, this method is too cumbersome for routine use due
to the time-consuming nature and low efficiency and reproducibility of the preparation. In
contrast, fluorescent stains such as ThT (Thioflavin T), a benzothiazole dye, (Figure 1. 22a)
only shows fluorescence upon binding to a specific molecular entity (e.g. amyloid misfolded
aggregates or fibrils). It is commonly used as a diagnostic tool for mature amyloid fibril
structures both in vitro and in vivo and Vassar et al. was the first to demonstrate this feature in
1959 [194, 195]. They reported that ThT will selectively bind to amyloid deposits, leading to
a significant increase in fluorescence brightness as shown in Figure 1. 22b and 22c.Further
investigations of the characterization of binding properties and fluorescence provided
fundamental support for the importance of the ThT spectroscopic measurement. As the
example shows in Figure 1. 22e, Lindgren et al. [196]demonstrated the dye thioflavin T
spectroscopic as an efficient method to monitor in situ process of amyloid aggregation with
different concentration conditions. In this study, a dramatic increase in the emission
fluorescence spectrum upon binding to amyloid fibrils was firstly identified as shown in Figure
1. 22d, then the fibrillation kinetics was measured as the concentration increased [196].
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Figure 1. 22. Experimental techniques employing ThT. (a) Structure of ThT (top). The two planer segments of
ThT whose mutual rotation defines its chirality (bottom). (b) Early histology using Thioflavin-T to stain primary
kidney amyloid. (c) Total Internal Reflection Fluorescence microscopy (TIRFM) image of branched glucagon
fibrils stained with ThT. (d) Characteristic increase in ThT fluorescence upon binding to amyloid fibrils.(e) Protein
concentration effects on the fibrillization kinetics measured by ThT fluorescent. The rapid onset of fibrillization
induced through seeding is also shown [194-197].

In addition, Ban et al. [198] (Figure 1. 23) employed total TIRFM combined with the
thioflavin T (ThT) to observe and track the growth of individual fibrils directly. The ability to
follow the process of fibril growth provided the great opportunity to not only analyse the
kinetics of the reactions, but also for the testing and evaluation of potent inhibitors or
therapeutic targets.
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Figure 1. 23. (A)Time-course of fibril formation at pH 7.5 and 37°C monitored using ThT fluorescence. (B)
Observation of Aβ(1-40) amyloid fibril growth by TIRFM [198].

1.6.2.2 Fluorescence Lifetime Imaging Microscopy (FLIM)
Intrinsic fluorescence spectroscopy has been suggested as another method capable of directly
detecting the amyloid formation by specific spectral changes. Recently, Esbjorner et al. [199]
employed fluorescence lifetime imaging microscopy (FLIM) to monitor amyloid formation and
study the kinetics of aggregation of Aβ40 and Aβ42 during their cellular uptake and the following
trafficking activity in live neuronal cells. In this work, the changes in the fluorescence lifetime
of covalently linked dye label HF488 was sensitively recorded during the amyloid aggregation,
and this method was proved useful in determining the existence of β-sheet structures, which is
highly correlated with such lifetime. Figure 1. 24 below shows an example of kinetic
measurement of HF488-labeled amyloid fibril formation. The decreased fluorescence lifetime
is consistent with the deeper extent of the amyloid formation and the broader lifetime
distribution, and the further aggregation progress is in good agreement with the increasing
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population of aggregates. Moreover, the investigation of Aβ aggregation in the neuronal cells
provided vital clues for understanding the role of Aβ aggregation in pathogenesis of AD.

Figure 1. 24. Kinetics of HF488-labled Aβ40 Fibril Formation Monitored by Fluorescence Lifetime Imaging. The
colour coding of images and histograms relate to the colour bar on the right. The HF488-labeled Aβ40
concentration was 5μM, and the peptide was diluted into 50 mM phosphate buffer sodium at pH 7.4 [199].

1.7

High-Speed

AFM:

Combined

Structural-

Dynamics of Aβ Interactions
Since proteins are dynamic and the process of their misfolding or refolding are frequently
associated with different transient intermediates, such as partially folded aggregates and
spherical oligomers, very little is known about the mechanisms underlying these processes [107,
200, 201]. The difficulties in monitoring various structural Aβ forms or aggregates and lack of
understanding on the dynamics of these transition interactions have further hindered related
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research progress. While the development of bulk kinetics measurements such as ThT
spectroscopy and fluorescence spectroscopy have provided significant insight into protein
dynamics, they do not address the lack of understanding at the single molecule level. Even
though single molecule fluorescent studies have been utilized successfully for detecting and
tracking the amyloid formation process, there are still limitations in capturing structural
information. Alternatively, AFM has been extensively used for providing structural
information of single molecules, however, owing to its slow imaging speeds, i.e. several
minutes per scan, the real-time dynamic information of single molecules is not realized. This
is where the emergence of High-Speed Atomic Force Microscopy (HS-AFM) provides an
exciting opportunity to contribute to an integrated approach with the aforementioned
techniques; to enable the visualization of protein structural-dynamics. HS-AFM is beginning
to bridge the gap by decreasing structural imaging times from minutes to milliseconds. It
massively surpasses the capabilities of current AFM systems by enabling acquisition times of
~50 milliseconds per image (~ 20 frames/second). This takes AFM into the realm of video rate
imaging that is defined as achieving speeds of ~ 12-13 frames/sec; the human eye needs to
visualize a sequence of images at this speed in order to perceive motion.
To study the dynamics of proteins, single-molecule fluorescence microscopy [202, 203]
and optical trapping apparatus [204] have been created and widely used over the last 20-30
years. These methods are reliant on recording the dynamic behaviour of optical biomarkers
attached to the protein molecule of interest. Owing to this indirect measurement, one has to
infer how the protein molecules are actually behaving behind the recorded data. Thus, a
technique capable of directly observing both structure and functioning protein molecules in a
“label-free” manner has long been desired. And to meet this desire, high-speed atomic force
microscopy has been developed [205-207]. (Figure 1. 25)
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Figure 1. 25. Schematic illustration showing HS-AFM system and devices. (a) All devices contained in the HSAFM system and main devices like different functional scanners, the stage designed for sample and cantilever,
and piezo control platform. (b) SEM image of a small cantilever for HS-AFM. The inset shows an electron beam
deposited tip grown on the original tip. (c) An advanced scanner designed for narrow scanning area imaging [207].

Over the past decade various developments in HS-AFM, including small modified
AFM cantilevers (Figure 1. 25b), sample-stage advanced scanners (Figure 1. 25c) and
optimised electronics shown in HS-AFM system (Figure 1. 25a), e.g. dynamic PID controller
[208] and cantilever deflection detection system, have seen the practical use of HS-AFM come
to fruition and used to address biological questions that have been difficult or impossible to
address by other methods [209]. For example, a feedback control system has been implemented
to maintain weak tip-sample interactions and an active damping method was introduced to
eliminate scanners’ mechanical resonant vibrations [210], which is responsible for the imaging
rate, however, perhaps the most critical development was the fabrication and ability to
accommodate the optical detection of very small cantilevers of ~6-12μm in length and 2μm
wide to achieve high resonant frequencies of ~400 kHz to 1.2MHz in water (1.5MHz to
3.5MHz in air) yet retaining small spring constants (~0.1-0.2N/m) that are suitable for imaging
biomolecules. In addition, an electron beam deposited sharp tip (~1μm long and apex radius of
~0.5nm in best case) can be post-fabricated by scanning electron microscopy (SEM) at the top
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end of the original cantilever to acquire high resolution images. Imaging speed of HS-AFM is
determined by various parameters, including the bandwidth of feedback control, scan range,
scan lines, the spatial frequency and maximum possible phase delay. At present, the imaging
rate has been greatly improved to over 20 frames per second (fps) without any significant
disturbance to the biological function (e.g. tip force action on the sample) [207, 211, 212].
Because of the high imaging rate and low invasiveness to the sample, HS-AFM enables the
directly visualization of dynamic structural changes and dynamic interactions occurring in
individual molecules, which contribute directly to a wide development of single molecule
dynamics visualization and major studies are list below [209]. (Table 1.3)

Table 1. 3. Studies on the dynamic events of proteins by using HS-AFM

Conformational
Changes

Diffusion and
interactions in
membranes

-Photo-activated bacteriorhodopsin [213, 214]
-Visualization of the motion of the Ca2+-pump [215]
-Rotary catalysis of rotorless F1-ATPase [216]
-Agonist-induced height change of NMDA receptor [217]
-Diffusion and fusion of vacancy defects in streptavidin 2D
crystals formed on SLB [218]
-Membrane-mediated interaction between ATP-synthase crings [219]
-Interaction of bR trimers with bR crystal edges in purple
membranes [220]
-Amyloid-like fibril formation by lithostathine [221]
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Self-assembly
processes
Dynamics occurring
in intrinsically
disordered proteins
DNA–protein
interactions
Diffusion and
interactions on live
cell surfaces

-Real-time visualization of assembling of a sphingomyelinspecific toxin on planar lipid membranes [222]
-Visualization of intrinsically disordered regions of proteins
[223]
-Wiggling and shortening motion of a disordered region in
CENP-T [224]
-Cleavage of DNA by type IIF restriction enzyme [225]
-Single molecule imaging of diffusion of crowded porin
molecules on live bacterial outer surface [226]

One of the first striking results obtained by HS-AFM images was the direct
visualization of myosin V molecules walking along actin filaments. The ability to capture
molecular, dynamic behaviours (e.g. unidirectional movement of myosin V molecule with
hand-over-hand manner, unfolding of the coiled-coil tail, foot stomp events in ATP and the
lever-arm swing motor action) with different conformational structural transitions (Figure 1.
26) provided unprecedented insight [227].

Figure 1. 26. Visualization of walking M5-HMM molecules. (a) HS-AFM film strip showing unidirectional
processive movement of M5-HMM in 1μM ATP. Scan size: 130 * 65 nm2, scale bar: 30 nm. (b) Schematic of twoheaded bound M5-HMM (c) Schematic of the movement explanation in d and e.(d)(e) HS-AFM film strips
showing the hand-over-hand movement in1μM ATP. (d) Scan size: 150 * 75 nm2, scale bar: 50 nm (e) Scan size:
130 * 65 nm2, scale bar: 30 nm. All the images showing here are captured at scan rate: 146.7ms per frame [227].
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The application of HS-AFM to study amyloid fibril dynamics has also appeared
recently, with Watanabe et al. [228] revealing the structural features and assembly kinetics of
Aβ42 (Figure 1. 27). They revealed two different pathways of the fibril growth, including
straight fibrillation and spiral growth. In addition, the findings of initial fibril nuclei structure
dependent pathway and the bidirectional switching property between two growth models are
also presented for the first time. This finding is consistent with the two distinct steps
mechanisms named as dock-lock growth mechanism [229]: monomers will initially bind (dock
to) to the fibrils surface in a fast timescale and followed by a slower timescale step associated
with the lock process, which is involved with structure rearrangement.

Figure 1. 27. HS-AFM imaging of Aβ42. (A) Schematic diagram of HS-AFM measurement including HS-AFM
cantilever, sample (Aβ42 fibrils and intermediates) and substrate mica. (B) Clipped HS-AFM images at different
time point during the fibrils growth. (Scale bar, 300nm) (C) Height profile of selected part of the fibrils as labelled
(A to B) at 1800s [228].

S. Banerjee et al.[230] also successfully captured different forms of Aβ42 oligomers
with distinct structures and highlighted the dynamic significance of isolated cross-linked
dimers, pentamers and heptamers. In this study, they found out that oligomers as large as
heptamers are in a dynamic equilibrium with dimers and trimers, indicating the important role
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of these two key types of oligomers in targeting and further sequestering higher order oligomers,
which are considered possibly the most neurotoxic agents.

1.8 Overarching Aims
Within the amyloid hypothesis in Alzheimer’s disease, current focus has shifted to earlier
stages of amyloid beta (Aβ) peptide assembly, involving soluble oligomers and smaller
aggregates which are more toxic to cells compared to their morphological distinct fibril forms.
However, due to the diverse, parallel molecular interactions between various species at this
earlier stage, (referred to the lag time stage shown in Figure. 1.7) along with associated
monomer-dependent nucleation, elongation and fragmentation mechanisms, it become critical
to unlock the molecular-level kinetic pathways involved with these transition mechanisms.
Although the Aβ42 peptide has been extensively studied, the detail on their dynamic interactions
and associated kinetic analysis at the single molecule level is essentially void. This is due to
the challenge acquiring high resolution structural information while simultaneously measuring
the dynamics. For this reason, directly visualizing the first moments of Aβ nucleation and
subsequent growth into oligomeric forms or other amyloid assemblies has not been achieved
despite it being a critical step (in the lag phase) underlying the amyloid aggregation process.
Lastly, a growing number of nanomaterials have been introduced to modulate the Aβ42
interactions, with a view for potential applications in diagnostics and treatment of disease.
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Therefore, to gain a better understanding of the fundamental mechanisms of amyloid
interactions responsible for the Alzheimer’s disease, the thesis aims to use High-Speed AFM
to:

Aim 1: Characterize the structure and dynamics of single molecule Aβ42 peptides in liquid,
including the intermolecular interactions occurring between the different assemblies of the
peptide.

Aim 2: Directly visualize the real-time nucleation and growth mechanisms of single Aβ42
peptides by applying in-situ HS-AFM whereby the sample condition is modified during
imaging to initiate the growth mechanisms. Numerous factors confirmed to either inhibit or
promote the aggregation such as metal ions, temperature and pH will be investigated.

Aim 3: Investigate the interactions between single nanoparticles, namely silica nanoparticles,
and Aβ42 peptides and to establish HS-AFM methodology and analysis for general
characterization of protein – nanoparticle interactions at the single molecule (nanoparticle)
level.
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Chapter 2: Dynamics of Inter-Molecular
Interactions between Single Aβ42
Oligomeric and Aggregate Species by
HS-AFM
2.1 Introduction
Recent theory for pathogenies in Alzheimer’s disease (AD) implicate the accumulation of
soluble amyloid beta (Aβ) oligomers [32, 231], generally consisting of low molecular weight
monomeric, dimeric, tetrameric Aβ peptides [232], or higher molecular weight (~20 – 40
monomers) oligomers [190]. Due to their small size, high diffusion rate and permissivity to
biological interactions, they are evidently more highly toxic, particularly with high-affinity for
cellular ligands [233] e.g. neurosynapses. They are defined as basic proteins transformed into
toxic forms that are structurally very distinct from their insoluble amyloid fibril successors
found in plaques synonymous with AD [234, 235]. Their increasing discovery in patients [236],
along with a growing number of in-vitro and animal studies demonstrating their toxicity [237,
238], has seen a shift from earlier amyloid ‘cascade’ hypotheses [239, 240], based on plaque
and fibril neurodegeneration, toward understanding the protagonists of Aβ oligomer toxicity
[235], including effects of size, morphology, homeostasis and biodistribution, leading to
emergence of Aβ immunotherapies in clinical trials [137]. A fundamental challenge is
identifying which subset or specific species of Aβ oligomers, amongst the apparent structural
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diversity and polymorphism with transient states, are responsible for AD. Equally as important
to more broadly elucidate potential targets for AD therapies will be understanding the
molecular interaction kinetics that ultimately define the oligomerization pathway(s) leading to
the toxic populations.
Thioflavin T-based fluorescence kinetic studies on Aβ revealing classical sigmoid
growth kinetics [241-243], including initial lag, followed by nucleation and fibril formation
phases, enable quick interrogation of amyloid or fibrillation blockers, e.g. antibodies, or the
effects of amyloidogenic biological conditions such metal ion concentration [244, 245] and pH
[245, 246]. The lag phase and slope of the nucleation phase partially indicates the rate at which
oligomerization proceed however the kinetic contribution from specific, individual oligomer
species are not differentiated. From a structural perspective, x-ray crystallography, electron
microscopy and atomic force microscopy show that the oligomer species range from 2-50 nm
in size [245, 247], displaying diverse structures and assemblies. Emerging techniques such as
ion mobility coupled with mass spectroscopy enable measurement of Aβ oligomer population
distributions, revealing potential assembly pathways and specifically dodecamers as terminal
species that are yet to rearrange into a β-sheet structures and thus may represent toxic forms in
AD [247-249]. Single molecule fluorescence measurements can probe oligomers present
during the lag phase, showing they constitute a highly heterogeneous ensemble of species (~
40 molecules) indicative of having undergone a stochastic polymer-like assembly process [250].
Up until now, only single molecule force spectroscopy (SMFS) based on atomic force
microscopy (AFM) is used to experimentally determine single molecule kinetics parameters
(e.g. dissociation constants) of intra-molecular Aβ interactions [251]. However, this is
currently only configured for the interaction between two monomers [252, 253], effectively
limiting measurements to dimerization kinetics. Exploring kinetics of very early stages of
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oligomerization, with seemingly fast transition states, are investigated by theoretical and
computational simulations [254-256] in the absence of molecular-level experimental data.
To date, a significant mismatch exists between high resolution structural imaging with
poor temporal resolution versus inherently fast dynamic spectroscopy but which lacks the
ability to directly visualize molecular structure. This is where the use of high-speed AFM (HSAFM as shown in Figure. 1.25) provides a unique opportunity to study the molecular structural
determinants of kinetics by decreasing structural imaging times of single molecules from
minutes to millisecs, i.e. ~15-20 images per second [212, 257, 258]. Related to amyloid
peptides, HS-AFM studies report on the structural flexibility of α-synuclein monomers and
dimers associated with Parkinson’s disease [259], dynamic formation of Aβ protofibrils [228],
and structural dynamics of Aβ oligomers, including specified trimers, pentamers and heptamers
[230]. Here, we develop a new analysis based on HS-AFM movies to produce lifetime traces,
enabling the first extraction of kinetics assigned to inter-molecular interactions between
different types of single molecule Aβ42 oligomers and aggregate forms. In doing so, we
discover interesting kinetic phenomenon once the Aβ42 species reach dimensions associated
with larger aggregate species.
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2.2 METHODS
2.2.1 Preparation of Aβ solutions and reagents
Amyloid-beta protein fragment 1-42 (Aβ42 peptide) was purchased as a lyophilized solid and
more than 95% purity was guaranteed by HPLC from Sigma-Aldrich (High Performance
Liquid Chromatography). ADDL’s from Aβ42 peptide were prepared according to previous
methods of [190, 260]. Firstly, 1mg lyophilized solid peptides were dissolved in HFIP
(1,1,1,3,3,3-hexafluoro-2-propanol) to prevent aggregation and then aliquoted into 50 small
microcentrifuge tubes. After 30-minutes incubation at room temperature in a chemical fume
hood, the HFIP was allowed to evaporate for 60 minutes and the re-lyophilized peptides stored
at -20°C. Aqueous solutions were prepared by dissolving peptides into PBS (pH 7.4) at
concentration of 20 μg/ml and then vortex mixing for 20 sec prior to use.

2.2.2 Remodification of HS-AFM Cantilever Tips
High resonance frequency (0.8-1.2MHz) cantilevers with low spring constants (0.1-0.2Nm-1)
specially designed for High-Speed AFM (HS-AFM) imaging were obtained from Olympus
(BL-AC10DS). The silicon nitride cantilevers consisted of a beak-like tip upon which we
further deposited a carbon-based tip by electron-beam deposition (EBD) [261, 262]. The
carbon tip was sharpened by argon or oxygen plasma etching to produce a significantly smaller
tip radius of ~3 nm compared to the original tip (25-100 nm) of the commercial cantilever,
which enabled improved imaging stability and resolution [263, 264]. After imaging, the carbon
tip could be completely removed by plasma etching and the cantilever remodified for reuse.
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2.2.3 High-Speed Atomic Force Microscopy (HS-AFM) imaging in
liquid
To prepare samples for imaging, 2ul of 20 µg/ml Aβ42 peptide in PBS was pipetted onto a 1.5
mm diameter freshly cleaved mica disk on a glass slide (Cat No. 7101) and incubated for 2
mins. 2ul of fresh PBS was then added and pipetted in/out of the sample solution, and this was
repeated several times to exchange the sample solution in order remove excess Aβ42 peptides
that had not adsorbed onto the mica surface. The sample was then placed into the liquid cell
for HS-AFM imaging. HS-AFM imaging was performed using an ANDO-model (Research
Institute of Biomolecule Metrology Co., Ltd., Japan) in tapping mode with high frequency,
small cantilevers (BL-AC10, Olympus) remodified with the carbon-tip, as described above.
During imaging, the free oscillation amplitude of the cantilever was set to ~2 nm and the set
point amplitude was kept to  90% of the free amplitude. An XY scanner with range of 4 μm
* 4 μm and z scanner (700 nm) with scan speeds of normally 2-4 frames/sec for 500 nm scans

was used. For higher resolution scans of 200 nm 5-10 frames/sec was applied. for 200 nm *
200 nm or smaller area imaging. During imaging, a relatively large gain force can be applied
without any effects to the interactions to improve the quality of image owing to the short time
of force action (~100 ns). Thus in the experiment, different types of dynamic events occurring
in the biological environment can be visualized.

2.2.4 Data analysis of HS-AFM images
A Matlab computer program was developed to segment molecules in HS-AFM images. The
program had four main stages: 1) background image estimation; 2) background subtraction and
contrast enhancement; 3) image segmentation using the Otsu’s algorithm; 4) connected
component labelling and object measurement.
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In Stage 1, the background image was estimated by applying image erosion followed
by image dilation. Let 𝐼(𝑥, 𝑦) be an input HS-AFM image, where 𝑥 and 𝑦 are the horizontal
and vertical coordinate, respectively. To compute the eroded image 𝐼𝑒 , the pixel at location
(𝑥, 𝑦) was set as the minimum of all pixels in a local neighbourhood of image 𝐼:
𝐼𝑒 (𝑥, 𝑦) = 𝐦𝐢𝐧 𝐼(𝑅(𝑥, 𝑦))
In our experiments, the local neighbourhood 𝑅 was selected as a circular region of radius 15
centred at pixel location (𝑥, 𝑦). Next, to compute the dilated image 𝐼𝑏 , the pixel at location
(𝑥, 𝑦) was set as the maximum of all pixels in a local neighbourhood of image 𝐼𝑒 :
𝐼𝑏 (𝑥, 𝑦) = 𝐦𝐢𝐧 𝐼𝑒 (𝑅(𝑥, 𝑦))
The dilated image 𝐼𝑏 (𝑥, 𝑦) was considered as estimation of the image background.
In Stage 2, the background image was subtracted from the input image: 𝐼𝑑 = 𝐼 − 𝐼𝑏 .
The difference image 𝐼𝑑 contained mostly the foreground (i.e. the molecules). To improve the
contrast of the foreground and consequently the segmentation accuracy, the difference image
𝐼𝑑 was scaled linearly to the full intensity range [0, 255].
In Stage 3, the enhanced difference image was segmented using the Otsu’s algorithm.
In this algorithm, a threshold is applied to separate the image into two classes: foreground and
the image background. This threshold is selected to minimize the intra-class variance and
maximize the inter-class variance and. In other words, this algorithm increases the similarity
between pixels belonging to the same class, while decreases the similarity between pixels
belonging to different classes.
In Stage 4, connected component labelling was applied to each group of connected
pixels into a single region (molecule). For each region, several properties were measured,
including width, height, bounding-box coordinates, centroid, perimeter, area, and eccentricity.
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In addition, the length and width of peptides were validated using the cross-section analysis in
the Igor Pro software. Using the above properties, molecules were also tracked across multiple
frames of a HS-AFM video sequence.
However, we also applied the function of filter to some videos, especially for the height
measurement, to better observe the individual molecules and their dynamic interactions. Owing
to this, some darker regions may appear in these snapshot images and slightly affect the real
height value of peptides that adsorbed in these darker areas, then we did manually analysis
using line height profile in Igor (HS-AFM software) with the filter on versus off to calculate a
correction factor for the height data.
All the data collected from the experimental results were repeated more than three times
and the reproducible results were shown as representative group.
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2.3 Results/Discussion
2.3.1 Structural Dimensions of Different Aβ42 Species
HS-AFM images with scan sizes of 500 nm taken at imaging rates of 2 frames/sec were used
to characterize the structure and dimensions of the Aβ42 peptide. A representative snapshot of
a single frame at time = 10s revealed adsorbed peptides with surface density of  30-40
molecules/µm2, primarily comprising small, globular-like structures of different sizes (Figure
2. 1a). Corresponding movies with duration of 500 secs show the differently sized peptide
species with varying surface diffusion speeds (Supplementary Movie S1). For statistical
analysis of structural dimensions, Matlab software algorithms were firstly used to desegment
imported avi movies into individual frames followed by automatic threshold detection of frame
objects to obtain parameters such as area (nm2), width (nm), length (nm) and height (average
pixel intensity) (See Methods Section). In addition, tip broadening effects are expected to occur
when the object’s size is below the radius of tip curvature and therefore the lateral dimensions
still represent an overestimation [42]. Histogram analysis of the area showed three distinct peak
distributions at 180 nm2, 400 nm2 and 700nm2 (Figure 2. 1b), indicating the existence of at least
three different forms of Aβ42 peptide(s). From the width and length histograms (Figure 2. 1d
and e), the main peak distributions occurred at 15 nm and 20 nm, respectively, indicating the
size of the most abundant Aβ42 peptide species. In addition, a second peak distribution occurred
at higher values of 36 nm, particularly for the width (Figure 2. 1d) and a similar range of higher
values is observed in skewed (non-normal; right tail) histogram of length (Figure 2. 1e). Two
other main observations included a much smaller peak distribution between 6-12 nm (Figure
2. 1e, arrow) specifically for length and sampling of significantly higher values of ~ up to 100
nm but with no clear distribution (Figure A1). For the height, two clear peak distributions are
observed at ~ 2.8 nm and another at 9.2 nm (Figure 2. 1c).
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Figure 2. 1. Morphology and dimensions of Aβ42. (a) Representative HS-AFM image of Aβ species on mica
surface in PBS (Scan size: 500nm, imaging rate: 2frames/second). (b-e) Histograms of dimensions, area (b), height
(c), width (d) and length (e). (f) Representative HS-AFM images (from left to right) of Aβ15-20nm, Aβ36nm, AβAgg
and disordered or unstructured Aβ monomer.

The existence of different Aβ42 peptide species based on their size distributions indicate
that the preparation of samples from lyophilized solid peptides dissolved in 1,1,1,3,3,3hexafluoro-2-propanol (HFIP) does not result in pure monomers but instead leads to associated
oligomers and larger aggregates [265, 266]. This is somewhat contrary to the use of HFIP that
constitutes a method typically used to minimize peptide aggregation. Once the peptides are
resuspended in phosphate buffer saline they are immediately deposited onto the mica substrate
for HS-AFM imaging (approximately after 20-30 min) and subsequently rinsed to remove
excess free peptide. This sample preparation also does not allow sufficient time for the
formation of amyloid fibrils [267], which was intentionally undertaken to only focus on the
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interactions and dynamics of Aβ42 monomers, oligomers and larger aggregates as opposed to
the processes of fibril formation as done by several others in AFM studies [192, 268].
Similar rounded structures of Aβ42 peptide species with dimensions on the order of a
few nanometres up to tens of nanometres are routinely observed in Aβ40 and Aβ42 samples in
AFM studies [269, 270]. Without the use of any solvent in the sample preparation, Prabhu et
al. [271] similarly reveal a height range of 1.5-2.5 nm for Aβ42 to explain the presence of either
monomers or small oligomers. Using super sharp tips for AFM imaging, Mastrangelo et al.
[190] refer to low molecular weight (LMW) soluble Aβ42 oligomers mostly with height of ~ 12 nm and diameters ranging from 5-15 nm attributed to monomers or dimers (5-7 nm) and
tetramers (~10-15 nm). In the same study based on the HFIP method, higher molecular weight
(HMW) oligomers of 15-25 nm in diameter (reduced value after tip correction) with heights
ranging from 3-6 nm indicated stacking of 2-3 monomers/dimers units. The HMW oligomers
could also retain heights of 2nm, suggesting the formation of planar structures [190]. More
recently, Banerjee and Siddhartha et al using HS-AFM show similar Aβ oligomer structures
and distribution of sizes, including compact (5-7 nm), bilobed (20 nm) and larger aggregate
structures, though are differently assigned to specific trimers, pentamers and heptamers,
respectively [230]. A point of difference in this study is that a photochemical cross-linking
method is used to enable isolation of Aβ according to their size and purity, giving a priori
knowledge of the sample distribution.
Theoretical and experimental measurements give a size of ~ 1 – 1.5 nm for single Aβ
monomers [255, 272, 273], thus our HS-AFM observations clearly represent several monomers
and what appear to be mostly oligomers and larger aggregates. Previous AFM studies have
shown that the lateral dimensions of Aβ, often up to tens of nanometers, exceeds the most
probable height of 2 nm and which is also the case in this study. Specifically, the lateral
dimensions were shown to vary linearly with the height, suggesting that the latter is actually a
79

true representation, i.e. the Aβ is not perfectly spherical but more closely resemble oblate
spheroids [274, 275]. As mentioned above, similar sizes of Aβ42 measured by AFM have
previously been attributed to various forms, including pentamers, tetramers, and HMW
oligomers. Here, we refer to the most abundant distribution of Aβ species with peak
distributions of 2.8 nm and 15-20 nm (length-width) (and correlating to an area of 180 nm2),
as Aβ15-20nm, since defining an exact number of monomer units is difficult. For example, in this
compact structure (Figure 2. 1f, far left image) the individual monomers cannot be resolved
due to insufficient AFM tip resolution. The larger-sized species of 36-40 nm are referred to as
Aβ36nm and effectively relate to a doubling of size compared to Aβ15-20nm. The Aβ36nm form
corresponds to images showing a bilobed structure, consisting of two rounded, compact
structures lying planar on the mica surface (Figure 2. 1f, middle left image). Interestingly,
similar 20 nm bilobed structures were recently observed by Banerjee and Siddhartha using HSAFM and identified as pentamers produced using a photochemical cross-linking method
[230].We interpret Aβ36nm as consisting of significantly greater number of monomers, which
also retain a height of 2.8 nm, indicating a planar structural configuration. Aβ36nm may however
orientate themselves perpendicular to the substrate, giving a doubling in height of ~ 4nm but
the same footprint area as the Aβ15-20nm (Figure 2. 1f). This is responsible for a broadening of
the height distribution in the histogram (Figure 2. 1c) and evident in further analysis of height
values described below in Figure. 2.1c. The largest structures, presumably giving a peak area
distribution of 700 nm2, length/width values of ~ > 40 nm and up to 100 nm, and very distinct
height distribution at 9.2 nm are clearly larger aggregates and referred to as AβAgg (Figure 2. 1f,
middle right image). Furthermore, a small peak between 6 -12 nm for length (Figure 2. 1e,
arrow) combined with heights of ~1 nm is more closely indicative of structures equivalent to
dimensions of lower molecular weight (LMW) oligomers such as dimers, trimers or tetramers,
as described in previous AFM studies [276, 277]. To date, a range of Aβ42 oligomer structures,

80

generally referred to as amyloid-beta derived diffusible ligands (ADDLs), globulomers and
protofibrils, are described in several reviews [278-280]. Contrary to early theories on Aβ42
existing in only stable monomeric or dimeric states, Teplow et al and others [73, 281] reveal a
mixture of monomers, dimers, tetramers, and HMW oligomers, specifically ‘paranuclei’
(planar hexamers), stacked hexamers and dodecamers.
Additional less-well, structurally defined Aβ42 species, as opposed to the rounded
conformations of Aβ15-20nm, Aβ36nm , AβAgg , are observed transiently appearing in the HS-AFM
movies (Supplementary Movie S1) and a representative snapshot given in Figure 2. 1f (far right
image). However, due to their significantly lower heights of < 1 nm, they were not easily
identified by automated threshold detection for analysis. In fact, they were most noticeable
when observing movies as they appeared transiently, e.g. flickering of the height contrast, in a
scan area for < 1-2 sec, indicating their fast surface diffusion (Supplementary Movie S1).
Supplementary Movie S2 more clearly indicates the appearance of these species by freezing the
relevant frames. Separate AFM cross-sectional analysis show these Aβ42 forms to be  25-30
nm in size and ~ 1 nm in height (Figure A2). We suggest that these forms are associated with
significantly smaller, soluble Aβ42 monomers that are known to be largely disordered or
unstructured in solution [190], although exact details of their transient conformational states or
dynamics is unclear. Recent studies using FRET analysis show that both Aβ40 and Aβ42
comprise an ensemble of rapidly reconfiguring unfolded states, with no long-lived
conformational states [282]. Molecular dynamics simulations support that the peptides have
configurations consistent with random polymer chains, with the vast majority of conformations
lacking significant secondary structure [273, 283]. When considering tip broadening effects,
the measured size of 25-30 nm correlates to an estimated contour length of an unfolded Aβ42
monomer (i.e. 42 amino acids ~ 20 nm).
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Figure 2. 2. Scatter plots of different dimensions, width (a) length (b), height (c), versus area of Aβ species.

The relationship between the dimensional parameters (length, width, height, area) is
shown in Figure 2.2 to better understand the structural configurations of the different Aβ42
species. Importantly, it is noted that Figure 2.2 represents the preformed Aβ42 species arising
from the sample preparation, i.e. lyophilized peptide from HFIP followed by resuspension in
PBS, as opposed to their formation after deposition on the mica surface. Herein, the length
versus width shows a linear relationship (Figure A3), indicating the different peptide species
generally retain a spherical structure as their size increases, which is also qualitative evident in

82

the HS-AFM images in Figure 2. 1. Two different linear trends for width (or length) versus
area values are observed (Figure 2. 2a and b); the first trend (i) shows that as expected a change
in both width (or length) is proportional to the area. In contrast, the second trend (ii) shows a
significantly smaller, or negligible increase in width (length) as a function of increasing area.
This is due to the analysis method whereby the width and length are defined as increasing in
value in the y-scan and x-scan directions, respectively. Thus, the effective width or length
approaches zero if measured in the opposing scan direction. A height versus area plot reveals
a region (1) where the height remains constant at ~ 2.5 nm with increasing area up to 800 nm2
(Figure 2. 2c). This indicates preformed aggregates can exist as planar structures with constant
height and presumably form by the lateral addition of monomers. In contrast, regions (2) and
(3) show an increase in height, firstly to 4.8 nm and then 7.8 nm, respectively. Specifically, the
increase to 4.8 nm, while retaining the area of ~ 200 nm2, suggests this may be related to
perpendicular reorientation of the larger Aβ42 species, e.g. Aβ36nm, on the mica surface. At
heights of 4.8 nm, further increases in the area to 400 nm2, indicates the preformed aggregates
can increase in size in both 2D and 3D. However, no further height increases are observed for
areas of 200 nm2 and 400 nm2. This interestingly leads to a ‘jump’ in height and area to7.8 nm
and area 600-800 nm2, respectively, for the AβAgg. These discrete changes in height as a
function of area (Figure 2. 2c), suggests that there is likewise a formation of discrete, preformed
Aβ42 species, as opposed to randomly sized oligomers and aggregates, during the sample
preparation of peptides.

83

Figure 2. 3. Filmstrip from HS-AFM movies showing the diffusion of individual Aβ15-20nm (a), Aβ36nm (b), and
AβAgg (c) molecules. In each filmstrip, the solid coloured circle delineates the current frame position of the
individually tracked Aβ42 species, while dashed circles denote the series of positions from the previous frames.
(Imaging rate: 2frames/second)

2.3.2 Surface Diffusion and Interactions of Different Aβ42 Species
Matlab software was used to automatically track the motion of the different Aβ42 forms in
movies (2 frames/sec) for a duration of 20 secs. In addition to Matlab software analysis,
representative filmstrips showing their diffusion are given in Figure 2. 3 and further
corresponding movies in Supplementary, Movies S3, S4, S5. In each filmstrip, the solid
coloured circle delineates the current frame position of the individually tracked Aβ42 species,
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while dashed circles denote the series of positions from the previous frames. The distance
moved by the Aβ42 species decreases as their size increases from the Aβ15-20nm, Aβ36nm to Aβ70nm
(Figure 2. 3). Slopes of distance versus time plots of individually tracked Aβ15-20nm, Aβ36nm and
Aβ70nm further emphasizes the differences in diffusion speed (Figure 2. 4). Interestingly, ‘steps’
are found in the slopes of Aβ15-20nm and this occurs to a lesser extent for Aβ36nm but is not
observed for Aβ70nm (Figure 2. 4a). The steps are due to a significant increase in the distance
moved by the Aβ15-20nm, i.e. up to 40-50 nm, within the period of a few frames. Following these
steps, the Aβ15-20nm resumes its normal rate of diffusion. Reasons for the sudden bursts in
diffusion speed are not fully clear though may relate to changes in surface-absorption [284].
Quantitative analysis of the average mean square displacement (n = 10) is shown in Figure 2.
4b, corresponding to diffusion coefficients of 3.51±0.72nm2 sec-1, 0.77±0.38nm2 sec-1 and
0.39±0.22nm2 sec-1, respectively. Further analysis of the fast diffusing monomers in Figure 2.
1f (far right image) and Supplementary Movie S2 was not undertaken because these peptides
only existed in the scan area for a period of 12 frames, as mentioned above In this case, the
monomers are able to traverse an entire scan area of 500 nm within a few seconds, giving an
estimated speed of > 2500 nm sec-1. (See Table 2.1) It is worth mentioning that those unique
activities with increased sizes can be also explained by the AFM imaging artifacts that normally
caused by tracking a moving object [285].
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Figure 2. 4. MSD versus time plot of individually tracked Aβ15–20 nm (black), Aβ36 nm (red) and AβAgg (blue)
molecules. MSD = <| r(t) − r(0)2 |> ,where < > means the average, r(t) is the position of each molecule in
determined time t, r(0) is the reference position of each molecule. (b) Average diffusion coefficient of 8.7 ±0.44
nm s (Aβ15–20 nm), 1.1 ± 0.06 nm s (Aβ36 nm) and 0.4 ± 0.01 nm s (AβAgg) obtained by fitting slopes in panel a.
Errors are standard deviation, n = >10 molecules.
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Representative filmstrips show examples of commonly observed interactions between
the different preformed Aβ species, i.e. once deposited on the mica surface, namely where there
was either 2D formation of elongated structures or addition of species in the z-direction giving
increases in height (Figure 2. 5). For example, after 0.8 sec, an Aβ15-20nm (2) moves closer to
an AβAgg (3) until they undergo binding at 1.4 sec and remain as a complex (2+3) for the
remainder of the filmstrip (Figure 2. 5a). In this case, the complex (2+3) increases in widthlength (and area). At 1.6 and 3.4 sec, further interactions within the complex (2+3) show the
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Aβ15-20nm “rebinding” to the top of the AβAgg, causing an increase in height (stacking in Figure
2. 5a) but no significant change in the area. Following this in Figure 2. 5b, Aβ15-20nm (1) and a
new Aβ15-20nm (4) enter the scan area and both interact with complex (2+3) (4.0 secs), resulting
in elongation and formation a small, protofibril-like structure. To visualize the dynamics of the
entire process, see Supplementary Movie S6. These collective interactions involve interactions
occurring in the z-direction (2  3) and x-y direction (1  complex (2+3)  4), demonstrating
a combined growth process to form new Aβ species. In general, these types of interactions are
dynamic and qualitatively could be either short-lived or long-lived, for example, the protofibril structures were only transient compared to more stable HMW oligomer/aggregate
complexes.

Figure 2. 5. Filmstrip from HS-AFM movies showing (a) sequence of interactions between Aβ15-20nm (1 and 2)
and and AβAgg (3) involving binding of Aβ15-20nm (2) on top of AβAgg (3) (stacking to form complex 2 + 3). (b)
Continuation of sequence in (a) showing formation of elongated structure due to interactions of Aβ 15-20nm (1 and
4) with complex (2 +3). Scale bar:25nm. Imaging rate: 5frames/s
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2.3.3 Kinetic Parameters of Single Molecule Aβ42 Binding
The ability to directly ‘watch’ single molecule interactions in action between the different Aβ42
species provides a unique opportunity to quantify kinetics underlying the process of
oligomerization. Here, we quantify the binding kinetics by measuring the amount of time two
molecules spend in physical contact, which is defined by the formation of image contrast
between the two molecules. Significantly, we extract kinetic parameters, e.g. mean lifetime <t>
and dissociation rate constant, koff (1/<t>), for specific interactions between the Aβ15-20nm 
Aβ15-20nm, Aβ15-20nm  Aβ36nm, and Aβ15-20nm AβAgg (Figure 2. 6a-c). An important distinction
for this type of HS-AFM-based analysis is involvement of the peptide-surface (mica)
interaction and its role in diffusion-limited effects on the intrinsic association/dissociation rates
of the Aβ species. For instance, the Aβ species can come in contact via diffusion, after which
they undergo binding at a rate governed by their intrinsic association rate constant. Conversely,
the Aβ species dissociate with an intrinsic rate constant, after which they move apart via
diffusion. Therefore, the time spent in contact between two species is may be influenced by
diffusion, which as shown in Figure 2. 3 differs depending on the size of the Aβ species.
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Figure 2. 6. Single molecule kinetics data analysis based on HS-AFM. (a-c) HS-AFM filmstrips showing
interactions between (a) Aβ15-20nm-AβAgg, (b) Aβ15-20nm-Aβ36nm, and (c) Aβ15-20nm- Aβ15-20nm. Molecules in contact
(green ‘on) are in the bound state. Imaging rate: 5frames/s. (d-e) Representative traces of single molecule lifetimes.
(g-i) Life-time distributions for the bound state of (g) Aβ15-20nm-AβAgg, (h) Aβ15-20nm-Aβ36nm, and (i) Aβ15-20nm- Aβ1520nm. Distributions in (h) and (i) are fit to a single exponential decay.

For this analysis, the binding is directly visualized as being ‘on’ or ‘off’ (Figure 2. 6ac) to produce single-molecule lifetime traces (Figure 2. 6d-f) that are analogous to those
commonly obtained using fluorescence techniques, e.g. single molecule FRET [286, 287].
Supplementary Movies S7, S8, S9 show corresponding movies of the different Aβ interactions
represented in filmstrips in Figure 2. 6a-c. Life-time distributions for the bound state show a
single exponential decay law for the Aβ15-20nm  Aβ15-20nm and Aβ15-20nm  Aβ36nm (Figure 2.
6h-i), indicating a single step binding process that yields one characteristic lifetime for these
types of interactions. A mean lifetime <t> = 0.55 ± 0.22 sec, with dissociation rate constant
koff (1/<t>) = 1.82 sec-1, for the Aβ15-20nm  Aβ15-20nm compared to the Aβ15-20nm  Aβ36nm
with a mean lifetime = 0.72 ± 0.28 sec (koff = 1.39 sec-1), indicating the latter to some extent
forms more tightly bound complexes due to its slower dissociation rate. It could also be that
the slower dissociation rate is partially governed diffusion, whereby with the order of the
magnitude slower diffusing Aβ36nm on the mica surface, even weaker interactions are sufficient
to keep them in contact for measurable periods of time. In contrast, lifetime distributions for
the Aβ15-20nm  AβAgg show a randomized histogram of shorter-lived through to longer-lived
complexes (Figure 2. 6g), indicating a distribution of interactions energies or barriers that the
Aβ15-20nm  AβAgg complex must overcome in order to dissociate. When considering the
effects of diffusion, the AβAgg is also an order of magnitude slower compared to the Aβ15-20nm
and effectively static on the mica surface, with the an Aβ15-20nm acting as a faster diffusing
ligand. Under these conditions, the Aβ15-20nm diffusion may influence the dissociation rate,
however, it is not expected to significantly alter the energy landscape of the unbinding
pathway(s). Thus, the randomized histogram is suggested to be intrinsic to the Aβ15-20nm 
89

AβAgg interaction and is different to an exponential decay of lifetimes, indicating all molecules
undergo the same process with a single well defined energy barrier, as the case for the Aβ1520nm

 Aβ15-20nm and Aβ15-20nmAβ36n complexes in Figure 2. 6h-i.
Kinetic parameters for single molecule Aβ peptide interactions have only previously

been determined by another AFM-based technique, single molecule force spectroscopy
(SMFS). For the SMFS, a monomeric peptide is attached to a substrate, for example via a
heterobifunctional cross-linker molecule such as N-hydroxysuccinimide-polyethylene glycolmaleimide [288], and the opposing monomer is bound to the AFM cantilever tip [289]. By
bringing the peptide functionalized tip into contact with the substrate, the measurement of
single molecule unbinding forces as function of loading rate, referred to as dynamic force
spectroscopy (DFS), enables kinetic and thermodynamic parameters to be extracted, yielding
a useful comparison of koff and bond lifetimes. Yu et al. [253]carried out DFS measurements
to understand the amyloid related misfolding and aggregation of -synulein in Parkinson’s
disease. At pH 5, a single energy barrier to unbinding of single -synuclein monomers, or
dimer dissociation, gave koff of  3.74 ± 1.99 sec-1 with lifetimes of 0.27 sec. More weakly
bound Aβ40 monomer-monomer interactions give koff of  9.4 ± 1.50 sec-1 with shorter
lifetimes of 0.1 ±0.01 sec at pH 7 [290]. Lv et al. [251] compared both Aβ40 and Aβ42, giving
koff of 9.0 ± 2.4 sec-1 (0.11 ± 0.03 sec) and 5.7 ± 0.3 sec-1 (0.18 ± 0.01 sec), respectively,
revealing stronger inter-peptide interactions for Aβ42 than for Aβ40. Specifically for Aβ42
monomer-monomer unbinding, Hane et al. [291] tested multiple DFS models (Bell-Evans and
Friddle-De Yoreo), giving koff of  7-12 sec-1 with lifetimes of 0.14 – 0.09 sec, while
comparable koff of  12.5 ±9.62 sec-1 and lifetimes of 0.09 ±0.7 sec were obtained in a further
study on the effect of copper ions [292]. From these SMFS studies, it is now understood that
Aβ dimeric complexes have high stability, dissociating over a period of seconds, i.e. ~5 – 12
sec-1, due to the monomers adopting antiparallel binding structures as shown in MD simulations
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[293]. This is very different to intramolecular interactions of monomers that occur on much
shorter micro-to-nanoseconds timescales [294], suggesting that the dimerization process
measured in SMFS may be an important protagonist in the early aggregation process. To date,
the peptide functionalization in SMFS studies is only configured for the interaction between
two monomers [252, 253] i.e. dimerization, though it is expected that clever functionalization
strategies in future will enable SMFS on a range of Aβ oligomer structures. Using our HSAFM-based analysis theoretically allows for kinetic information on multitude of combinatorial
Aβ interactions, including those consisting of multiple monomer units.
Table 2. 1. Summary of properties of different Aβ species
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2.4 Conclusions
Significantly, the HS-AFM analysis suggests that the formation of aggregates such as Aβagg
are driven by kinetic heterogeneity, indicating a shift in the mechanism of oligomerization. We
attribute this “opportunistic” or permissive binding to the presence of different conformation
states of the Aβagg, resulting in a variety of accessible interacting groups. Inevitably, this is
likely to lead to the formation of different complexes or alloforms, which is known to
contribute to the complexity and challenges in identifying Aβ oligomer toxicity. Equally for
ensemble kinetic measurements, nucleation-limited aggregation of Aβ40 peptide is shown to
be controlled by a stochastic factor inherent in the nucleation process, leading to substantial
macroscopic heterogeneity [295]. More recently, Nag et al. [296] refer to ‘metastable’ Aβ40
oligomers that are thermodynamically unstable but show a large kinetic barrier, which is mostly
entropic in origin. The monomers are said to be entangled in the initial oligomeric state, with
multiple intra- and intermolecular hydrophobic interactions aiding in their entanglement. At
the single molecule level, Orte et al. [297] recently report on stochastic behaviour in early
stages of oligomer fibril formation by the SH3 domain from bovine phosphatidylinositol-3_kinase (PI3–SH3). Using two-color single-molecule fluorescence they show that although the
size distribution of detected SH3 oligomers remains virtually constant with increasing
aggregation time, they constitute a highly heterogeneous ensemble of species, which is
explained by a stochastic polymer-like assembly process [297]. Molecular dynamics
simulations of the early steps of aggregation provide evidence that the associating and initially
monomeric polypeptide chains can sample and stabilize early aggregates of considerably
different structures [298], with considerable conformational flexibility, thereby enabling the
formation of very different conformational arrangements [299]. Such observations are
testament to oligomers showing a high degree of polymorphism, as a result of stochastic
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fluctuations in polypeptide chain dynamics. Evidence is increasingly pointing to heterogeneity
as a protagonist in aggregation. For example, variations in oligomer conformation and
associated interactions, and not just specificity in oligomer size, may be responsible for
biological toxicity, as demonstrated for HypF-N protein [300]. Our study contributes to this
emerging narrative by quantifying the kinetic parameters of different Aβ species consisting of
oligomers and aggregate forms, in particular confirming a distinct change in the energy
(binding) landscape occurring at the onset of interactions with aggregate species, i.e. AβAgg.
In conclusion, single molecule kinetic data can make significant contributions to
‘kinetic’ distribution models that depict aggregation pathways, but which still lack the
assignment of fully quantitative kinetic constants to their various pathways. The sizes and
distribution of Aβ42 species presented here agree with previous AFM studies but in particular
the HS-AFM movies emphasizes the dynamic and transient states that exist within and between
the different species. In assimilating to current models, the findings show that interactions
between smaller Aβ species (Aβ15-20nm and Aβ36nm) present a single exponential decay of
lifetimes, while interactions with larger aggregates is driven by a type of kinetic heterogeneity.
The latter enables the formation of long-lived, stable Aβ aggregates. It is necessary in future
HS-AFM studies to investigate the influence of peptide-surface interactions and diffusion
parameters on quantitative analysis of kinetic parameters; though such studies are also relevant
to the effects of cell membrane surfaces and other intracellular substrates that may play a role
in the formation of Aβ oligomers/aggregates. In addition, implementing well-defined Aβ
peptides, e.g. comprising recombinant peptides or those with structures known a priori, will
assist in rationalizing AFM characterization of peptide dimensions and together with new
insights on Aβ dynamics from HS-AFM, exciting advances in understanding Aβ42 interactions
can be explored.
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Chapter 3: Visualizing Real-Time
Nucleation and Growth Mechanisms of
Single Aβ42 Oligomers
3.1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the presence of
senile plaques and neurofibrillary tangles [301-305]. Recent studies on the conformational
structure and aggregation of Aβ species have revealed that a subset of soluble, non-fibrillar Aβ
[46, 72], referred to as amyloid β-derived diffusible ligands (ADDLs) [58, 68], are primarily
responsible for neurotoxicity instead of fibril-induced neuronal death described by the earlier
“amyloid cascade hypothesis” [34]. Several studies have shown that soluble oligomeric Aβ
species may be the initial effectors of neurodegeneration rather than Aβ fibrils [306-309].
Similarly, for all types of Aβ peptide assemblies, the soluble oligomers and larger aggregates
formed during the Aβ aggregation are reportedly more toxic than some initial species such as
monomers [59, 104, 310].
Evidently, the molecular mechanisms and kinetics associated with the formation of
pathological Aβ oligomers and aggregates, involving monomer-dependent nucleation
processes is of significant interest. In primary nucleation, the growth of individual nuclei only
involves monomer addition and can occur in bulk solution (homogeneous nucleation) or at a
surface which is not already made up of the monomer (heterogeneous nucleation). A monomerdependent secondary nucleation process, whereby the surface of an existing structure made up
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of the same monomer, e.g. amyloid fibril, “catalyses” the growth of new nuclei, was more
recently discovered for Aβ42 and since demonstrated for other proteins such as islet amyloid
polypeptide and α-synuclein in Parkinson’s disease [103, 311-313]. This secondary nucleation
mechanism explains the shortening of the lag-phase fibril growth through addition of preformed fibrils, or “seeds”, into a monomer solution. As mentioned, while the general consensus
is that toxicity is mainly associated with oligomers above the amyloid fibrils, recent in vitro
studies further reveal a strong toxic effect from Aβ oligomers produced by secondary
nucleation of monomers on fibril surfaces [104, 314, 315]. Herein, an understanding of these
nucleation processes, leading to the formation of toxic oligomers, serves to identify potential
therapeutics that either control or inhibit their growth process.
Various studies have shown that an acidic pH environment, higher peptide
concentration, extending incubation times, and even the presence of a solid substrate are
important predictive factors in promoting amyloid deposition [316-319]. Moreover, in-vitro
studies have shown that Aβ is not an intrinsically insoluble peptide and the solubility (and
toxicity) of Aβ peptide is critically dependent on the aqueous environmental conditions such
as pH [320, 321]. For example, the α-helical structure of Aβ42 is favoured at pH 1 to 4 while
the neurotoxic β-sheets as well as fibril formation occur under acidic conditions from pH 4 to
7 [320, 322-324]. In addition, Aβ42 peptides are shown to self-assemble rapidly from insoluble
aggregates into fibrils at pH 5.0 in comparison with pH 7.4 [316, 317]. By reducing the pH to
4.6, the native conformation of Aβ peptides can change into less-ordered structural aggregates
during the fibril growth stage [325]. Klug et al. [326] also demonstrated that Aβ aggregation
induced by low pH occurred via a different pathway that is associated with slow aggregation
process of stable Aβ species.
Studies on the effect of peptide concentration have reported that Aβ40 formed a stable
dimer at relatively low concentration of 25 µg/ml, while high concentrations significantly
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promoted the formation of helix structures, which are believed to inhibit or slow fibrillogenesis.
Thus, the latter leads to greater formation of intermediate aggregates [327, 328]. Lomakin et
al. have demonstrated that there is a critical Aβ concentration for the aggregates to
spontaneously initiate fibrillogenesis [191, 329]. In addition, the rate of nucleation depends on
both the aggregate and monomer concentrations [104].
Monomer interactions with surfaces can also play a role, with two main factors
(intrinsic and extrinsic) widely reported to affect the monomer-dependent nucleation processes
and subsequently alter the lag phase [103]. For example, a growing number of mutants in Aβ
sequence variants in the amyloid precursor protein (APP) gene (e.g. A21G (Flemish), E22G
(Arctic), E22K (Italian), E22Q (Dutch) and the D23N (Iowa) amino acid substitutions) have
been identified as beneficial intrinsic agents for clinical relief treatment [330-332]. Extrinsic
factors generally include other peptides and proteins [333-336], membranes [337, 338],
nanoparticles and substrates [339-344], smaller molecules [345, 346], pH and temperatures
[104, 347, 348]. In particular for the effects of surface area, where the catalysis or inhibition of
aggregation will be determined by the protein to surface area ratio and the strength of surface
attractive forces [342, 349].
Theories of Aβ monomer-dependent nucleation processes are based on macroscopic
kinetic measurements showing classical sigmoid shaped curves that typically consist of three
different phases, including lag, growth and plateau phase [350, 351]. During the lag phase,
which generally represents the time that is required for nuclei to grow, there also exists a myriad
of diverse, parallel molecular interactions occurring between different species, such as the
nuclei, intermediates, oligomers and aggregates, involving the aforementioned monomerdependent nucleation as well as other elongation and fragmentation processes [352-354]. In
fact, many of these molecular interactions are ongoing during all phases, and the overall
macroscopic (averaged) measurement cannot distinguish between the different molecular
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interactions. In particular, the initial nucleus are suggested to form within milliseconds, though
characterizing such molecular events at short-timescales in bulk analysis where the detection
sensitivity is limited, e.g. not enough aggregate has formed, is a challenge [355, 356]. The
concentration of oligomers is also low and they are also highly transient, similarly making it
difficult to elucidate their role in the growth process and compounded by a lack of experimental
techniques to directly quantify kinetics of single molecule Aβ species. Therefore, there remains
the question as to which molecular interactions occur during these phases, particularly at early
time-points where nuclei, oligomer and aggregate species are produced, as this is important for
understanding the fundamental mechanisms of amyloid formation.
Herein, we use High-Speed Atomic Force Microscopy (HS-AFM) to directly visualize
the formation and growth of nuclei, followed by their subsequent interactions with existing
seeds and inter-molecular interactions to produce new aggregates. HS-AFM enables the
visualization of protein structural-dynamics and is beginning to bridge the gap by decreasing
structural imaging times from minutes to millisecs [357]. It massively surpasses the capabilities
of current AFM systems by enabling acquisition times of ~50 milliseconds per image (~ 20
frames/second). This takes AFM into the realm of video rate imaging that is defined as
achieving speeds of ~ 12-13 frames/sec, coupled with the ability to achieve 1-2 nanometer
lateral image resolution, this technique has recently been used to visualize dynamics of Aβ in
‘action’, including the interactions between single oligomeric and aggregated species [358].
We specifically investigate Aβ on a solid substrate (mica), where a local concentration of
diffusing monomers exist at the liquid-solid interface, and through a pH-triggered nucleation
process are able to directly visualize the growth of single nuclei followed by the formation of
single oligomers and aggregates in real-time.
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3.2 Materials and Methods
3.2.1 Preparation of Aβ42 samples
Amyloid-beta protein fragment 1-42 (Aβ42 peptide) was purchased as a lyophilized solid and
more than 95% purity was guaranteed by HPLC from Sigma-Aldrich (High Performance
Liquid Chromatography). Aβ42 peptide samples were prepared according to previous methods
of [319, 347]. 1 mg of lyophilized solid peptides were firstly dissolved in (1,1,1,3,3,3hexafluoro-2-propanol (HFIP) to prevent aggregation and then aliquot into 50 small
microcentrifuge tubes. After 30 minutes incubation at room temperature in a chemical fume
hood, the HFIP peptide solutions were allowed to evaporate for 60 minutes and the relyophilized peptides stored at -20°C. Lyophilized peptides were solubilized using phosphatebuffed saline (PBS) (pH 7.4) at a concentration of either 20 µg/ml, 50 µg/ml or 100 µg/ml and
then vortex mixing applied for 20 seconds prior to use. To investigate the effect of pH on
peptide samples, two different methods were used. The ex-situ method involved either
maintaining a pH of 7 (i.e. using the peptide samples solubilized in PBS) or adjusting the pH
to 3 or 11 by addition of HCl or NaOH prior to depositing the peptide solution on a mica
substrate for HS-AFM imaging, as described below. Alternatively, the in-situ method involved
firstly depositing the peptide solution in PBS (pH 7) for HS-AFM imaging and then during the
imaging using a pipette to inject 2 µl of concentrated HCl or NaOH into the sample solution.
After ‘spiking’ the sample solution, further mixing could be applied by withdrawing/injecting
the solution via pipetting.

3.2.2 High-Speed Atomic Force Microscopy
To prepare samples for imaging, 2 µl of the Aβ42 peptide solution was pipetted onto a 1.5 mm
diameter freshly cleaved mica disc (Cat No. 7101) and incubated for 2 minutes to allow the
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peptides to adsorb onto the mica surface. 2 µl of fresh PBS was then added and pipetted in/out
of the sample solution, and this was repeated several times to exchange the sample solution in
order to remove excess Aβ42 peptides that had not adsorbed onto the mica surface. The sample
was then placed into the liquid cell of the HS-AFM. HS-AFM imaging was performed using
an ANDO-model (Research Institute of Biomolecule Metrology Co., Ltd., Japan) in tapping
mode with high frequency, small cantilevers (BL-AC10, Olympus) remodified with the
carbon-tip, as described above. During imaging, the free oscillation amplitude of the cantilever
was set to ~2 nm and the set point amplitude was kept to  90% of the free amplitude. The
maximum possible scanning rate is calculated as Rmax= (λƒ)/(2WN), where λ is the amplitude,
ƒ is feedback bandwidth, W is the scanning size and N is the corresponding number of scan
lines. A non-electrode wide scanner with range of 4 μm * 4 μm, z scanner with maximum
height of 700 nm were used with typical scan speeds of 2-4 frames/sec for 500 nm scans.
Higher resolution scans of 200 nm were taken at 5-10 frames/sec with 550-275 lines/sec. HSAFM imaging was performed on samples of different peptide concentrations (20 µg/ml, 50
µg/ml or 100 µg/ml), incubation times (1h, 2h and 4h) of the peptide in the PBS (pH 7) prior
to commencing the imaging, and pH of 3, 7, and 11 using either the ex-situ or in-situ method.
The imaging was performed for a typical duration of 10 minutes to 120 minutes or until it was
clear that tip quality had reduced, presumably due to adhesion of peptides on the tip. For each
sample condition at least three separate imaging experiments using new tips were performed.
The operation of the HS-AFM and collection of the AFM movies was obtained by modified
software in Igor Pro, Wave metrics. AFM movies were either analysed using Igor Pro or
exported as an AVI. Movie file for further analysis using Matlab algorithms.
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3.2.3 Statistics analysis
Values obtained from the Matlab analysis of HS-AFM movies included the peptide area,
intensity (height), width and length as mentioned in Chapter 2. All data analysis and histograms
were produced using Igor Pro, Wave metrics. Multi-peak fitting with Lorentzian or Gaussian
functions were applied to the histograms. The peak values shown in histograms are
representative size of each species of peptide (with error bars indicated). Origin was used to
plot the peptide area versus intensity in Fig.3.1, 3.2, 3.3 (g, h, i).
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3.3 Results/Discussion
3.3.1 Ex-situ Aβ: Effect of concentration, incubation time and pH
3.3.1.1 Concentration
Ex-situ preparation of samples was used to assess the effect of sample conditions such as Aβ
concentration, solution pH and incubation time on the formation of oligomer or aggregate
species. The Aβ42 peptide was resuspended in PBS solution (in Eppendorf tubes) at either
different Aβ42 concentrations of 20, 50, 100 µg/ml or pH of 3, 7, or 11 (20 µg/ml Aβ42 in PBS
by addition of HCl or NaOH). After approximately 30 minutes, these samples were deposited
on the mica surface and imaged with the HS-AFM. To investigate the effect of time, 20 µg/ml
Aβ42 solutions at pH 7 were incubated for either 1 hr, 2 hr or 4 hr prior to imaging with HSAFM. In all samples, HS-AFM imaging commenced ~ 2-5 min after the peptides had been
allowed to adsorb to the mica, i.e. the time required to align the laser and approach the tip to
sample surface. Three representative snapshots taken from HS-AFM movies at 1.0 frames/sec
at time = 1.0 sec of Aβ42 peptides prepared with solution concentrations of 20 µg/ml, 50 µg/ml
and 100 µg/ml are shown in Figure 3.1A-C. Corresponding movies with duration of 500 secs
(supplementary Movie S1, S10 and S11) show the peptide dynamics, particularly their surface
diffusion and, in many cases, physical interactions occurring between the peptides. For 20
µg/ml samples at pH 7, particulate or globular structures of various sizes were observed with
surface density of ~30-40 molecules/µm2 and exhibited three area distributions at 170 ±34nm2,
410 ± 67nm2 and 645 ± 37nm2 and two height distributions at 3.2 ± 1.2nm and 7.7 ± 0.8nm
(Figure 3.1a and 3.1b). These different distributions of the Aβ dimensions are in agreement
with the three main species observed in the previous chapter, referred to as Aβ15-20nm, Aβ36nm
and Aβagg, and ascribed to the existence of Aβ42 oligomers and larger aggregates that represent

102

pre-formed species arising from the sample preparation, i.e. lyophilized peptide from HFIP
followed by resuspension in PBS, as opposed to their formation after deposition on the mica
surface. Increasing the Aβ42 sample concentration to 50 and 100 µg/ml retained the three main
distributions for area though the peak values appeared to shift to lower values (Figure 3.1a-c),
while the lower height distribution clearly showed an increase in peak value to the point where
at 100 µg/ml the two height distributions effectively coalesced to form a single distribution.
Scatter plots of the height (pixel intensity) versus area (Figure 3.1g-i) with identical scales also
clearly distinguished the 3 main Aβ42 distributions at 20 µg/ml (Figure 3.1g), which were
increasingly overlapping and less distinct at the higher concentrations of 50 µg/ml (Figure 3.1d)
and 100 µg/ml (Figure 3.1f). Aβ with concentration range from 20 µg/ml to 100 µg/ml
deposited on mica surface all exhibited three main populations although a slightly decrease in
area and increase in height occurred with increased concentration, suggesting an interesting
trend: the decreasing peptide size is correlated to the increasing height, and the Figure 3.1g-i
showing relation between these two parameters indicated the tendency toward formation of a
single population.
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Figure 3. 1. Morphology and structural dimensions of different concentration Aβ42 peptides. (A-C) Representative
HS-AFM image of 20 µg /ml, 50 µg /ml and 100 µg /ml concentrated Aβ42 peptides diffuse on the surface of mica.
(Scan scale: 500*500nm, imaging rate: 1frame/second. (a-f) Histograms of different structural dimensions
distributions. Area (a, c, e), Height (b, d, f). (g-i) Scatter plots of area and height shows their relationship.

3.3.1.2 Incubation time
Starting from intact lyophilized solid peptides, and then after 1 h, 2 h or 4 h incubation in PBS
at neutral pH 7, the peptides were imaged at 1 frame/sec with a scan area of 500nm.
Corresponding snapshots from movies of peptides after 1 h incubation are equivalent to those
in Figure 3.1A that were taken under the same conditions (i.e. 20 µg/ml, pH 7 and 1 h
incubation) and displayed in Figure 3.2A again for comparison with the longer incubation times.
(Supplementary Movie S1, S12 and S13) After 2 h and 4 h incubation, three similar peak
distributions for area were observed in Figure 3.2c and Figure 3.2e, respectively. However,
there appeared to be no significant difference in the peak values compared to 1 h incubation.
In contrast, similar to increasing concentration, increasing the incubation time to 2 and 4 h
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resulted in a comparable increase in height of the peptides (Figure 3.2d and Figure 3.2f). At 2
h incubation, the main height distribution increased to a peak value of 4.3 nm, with a further
increase to 4.6 nm occurring at 4 h incubation. Both of the longer incubation times also
continued to show the secondary distribution at higher peak values of 7.4 (2 h) and 8.6 nm (4
h) (Figure 3.2d and Figure 3.2f). Similarly, scatter plots of height versus area showed that the
three main populations became less distinct with increasing incubation time, primarily due to
the increasing height values. In summary, the effect of peptide concentration and incubation
time both showed the involvement of the three distinct area, and two height distributions of the
Aβ, as observed in the previous chapter (and displayed again for comparison in Figure 3.1A
and 3.2A). These arise from pre-formed structure in the sample preparation. It is observed that
by increasing either concentration or incubation time of samples prepared ex-situ, there is some
modification to these preformed structures, namely an increase in size apparent from a
measured increase in height by approximately 40-50%.
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Figure 3. 2. Morphology and structural dimensions of different incubation time Aβ 42 peptides. (A-C)
Representative HS-AFM image after 1h, 2h and 4h incubation of Aβ42 peptides diffuse on the surface of mica.
(Scan scale: 500*500nm, imaging rate: 1frame/second. (a-f) Histograms of different structural dimensions
distributions. Area (a, c, e), Height (b, d, f). (g-i) Scatter plots of area and height shows their relationship.

3.3.1.3 Effect of Solution pH
Filmstrip from HS-AFM movies of 20 µg/ml peptide samples at pH 3 (Figure 3.3A), pH 7
(Figure 3.3B) and pH 11 (Figure 3.3C) showed distinct differences, especially with regards to
the presence of larger Aβ peptides formed under acidic conditions. (Supplementary Movie S1,
S14 and S15) In addition, a significantly lower number of adsorbed peptides with surface
density ~10-20 molecules/µm2 were observed under alkaline conditions (pH 11) compared to
neutral and acidic pH, with values of ~30-40 molecules/µm2 and ~55-66 molecules/µm2,
respectively. Compared to the histogram analysis of the neutral solution condition (plotted in
Figure 3.3B for comparison), only two peak distributions for area at 251 nm2 and 620 nm2 were
observed for pH 3 (Figure 3.3a), with the former, main distribution representing almost a
doubling in size of the peptides. In addition, the two peak height distributions showed an 5080 percentage increase in size to 4.3 nm and 13.5 nm (Figure 3.3b), which again was equivalent
to a ~ doubling in height compared to the pH 7. It is worth mentioning that the observation of
proto-fibrils and mature fibrils were also achieved after longer incubation time in pH 3,
(Supplementary Movie S16, S17 and S18) however, no further analysis was conducted due to
the fact that species formed at early stage are of more interest. In contrast, at pH 11, only one
peak distribution for area was observed at 108 nm2 (Figure 3.3e), corresponding to a single
height distribution of 2.5 nm (Figure 3.3f). Scatter plots of the height versus area interestingly
showed that at pH 3 the peptides from the main distribution for area with peak value of 251
nm2 were responsible for both height distributions. For example, most of the peptides within
the main area distribution corresponded to heights of 4.3 nm, but a smaller sub-population
corresponded to the heights at 13.5 nm, i.e. values > approximately 300 pixels in Figure 3.3g.
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Furthermore, the larger area peptides at 620 nm2 actually had similar heights to those smaller
peptides representing the main distribution (Figure 3.3g). Evidently, under the alkaline
conditions the scatter plots confirmed the existance of only a single distribution of peptides
(Figure 3.3i). Owing to the huge changes under the acidic conditions, we further pursued the
effect of low pH for in-situ experiments, as described below.

Figure 3. 3. Morphology and structural dimensions of Aβ42 peptides incubated in different pH solution. (A-C)
Representative HS-AFM image of Aβ42 peptides diffuse on the surface of mica in different pH solution. (Scan
scale: 500*500nm, imaging rate: 1frame/second. (a-f) Histograms of different structural dimensions distributions.
Area (a, c, e), Height (b, d, f). (g-i) Scatter plots of area and height shows their relationship.

3.3.2 In-situ amyloid beta nucleation process
In the previous chapter and this study, the different Aβ oligomers and aggregates are already
pre-formed or assembled during the sample preparation and prior to deposition on the mica
surface. However, an understanding of their origin and formation directly from the Aβ
monomer requires observations of early stages such as initial nucleation steps and subsequent
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growth. Since the range of Aβ concentration and incubation time used in ex-situ sample
preparation resulted in only pre-formed structures, with relatively small change in their
dimensions, it was not expected that these sample conditions would enable in-situ HS-AFM
observation of dynamic nucleation and/or growth processes, at least within the timeframe of
the HS-AFM experiments. Further to this, the typical duration of the HS-AFM imaging, e.g.
10mins – 2 hours, is significantly shorter than the general time (~ typically days) for Aβ42
aggregate or fibril formation, which is also dependent on various environmental factors [359,
360]. In contrast, low pH, acidic conditions, produced a greater number (~55-66 molecules/µm2)
of significantly larger oligomers or aggregates within a relatively short period of time, i.e. 2
hours. In addition, the difference in their morphology and dimensions (Figure 3.4a and 3.6a-b)
compared to pre-formed structures (Figure 3.3A-C) suggested that the low pH conditions
produced newly formed species and/or induced significant growth of the existing ones. These
observations are supported by previous studies that have shown differences in the dynamic
formation of the aggregates as a function of pH [361, 362]. Henceforth, it was anticipated that
changing to a low pH solution during HS-AFM imaging of the Aβ42 could enable in-situ
observations of dynamic pH-dependent processes. To perform these experiments, imaging was
initially performed at pH 7 for several minutes until the image was optimised. Whilst
continuing the imaging, 2 µl of a 1mg/ml concentrated HCl solution (or NaOH for comparison)
was then injected into the liquid cell. After an initial instability resulting in loss of the image,
the imaging could be resumed within approximately 20 seconds by adjusting the imaging
parameters.
A representative filmstrip with different time-points of an in-situ experiments involving
“spiking” with acidic solution is shown in Figure 3.4a. (Supplementary Movie S19) We were
able to identify four different phases during the imaging process, including i) pre-spike, ii) prenucleation, iii) nucleation, and iv) equilibrium growth. These are explained by correlating the
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filmstrip images in Figure 3.4a with quantitative analysis of the particle count (Figure 3.4b)
and r.m.s surface roughness (Figure 3.4c) versus the time. The particle count is a measure of
the number of nucleating Aβ peptides on the mica, while the surface roughness measured from
each movie frame is reflective of both the change in count and size of the particles, i.e. surface
roughness increases as more particles nucleate and grow. Prior to spiking with HCl, the Aβ
peptides are observed to be diffusing on the mica surface (Figure 3.4a, frame = 0 sec). During
this pre-spike phase (i) there was no significant change in the particle count (Figure 3.4b, frame
= 0-30 sec) and surface roughness (Figure 3.4c, frame = 0-30 sec). After spiking with HCl
(Figure 3.4a, frame = 30 sec), the perturbation by injecting the solution typically caused the tip
to lift from the surface, resulting in loss of imaging. In these cases, the set point oscillation
amplitude of the cantilever was re-adjusted to resume imaging of the surface within 20 secs.
Qualitative observations of subsequent frames from 30 to 130 sec did not clearly show a change
in the number of peptides on the mica surface, though some of the existing peptides showed an
increase in size (Figure 3.4a, frame – 30-130 sec). During this period, which was referred to as
the pre-nucleation phase (ii), the analysis of particle count showed an increasing fluctuation in
values between ~ 0-20 (Figure 3.4b(ii)), while the r.m.s. surface roughness showed a gradual
increase from 0.95 nm to 1.03 nm (Figure 3.4c (ii)). Thus, the pre-nucleation phase was
characterized by a slow rate of nucleation, involving possible formation of new Aβ and
increased growth of existing Aβ. Later on at 135 sec, a rapid increase in the appearance of
smaller peptides was observed, in addition to the continued growth of existing Aβ peptides.
Analysis of both particle count (Figure 3.4b (iii)) and surface roughness (Figure 3.4c (iii)) from
this time-point (135 sec) showed an increase in their values until ceasing at approximately 170
sec. Thus, this period between 135 – 170 sec was referred to as the nucleation phase (iii).
Beyond this period (Figure 3.4a, frame – 300 - 400 sec), referred to as the equilibrium growth
phase (iv), a significant number of the smaller peptides remained on the mica surface while
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both new and existing Aβ peptide continued to increase in size. This equilibrium growth phase
(iv) correlated to a slower rate of increasing r.m.s. surface roughness (Figure 3.4c (iv)),
however also showed an unexpected decrease in the particle count (Figure 3.4b (iv)). For the
latter, it appeared that the decrease in particle count was due to a decrease in those monomers
covering the mica surface, i.e. the mica appeared “cleaner” in regions during the growth phase
compared to the nucleation phase, suggesting the consumption of surface adsorbed species
during the nucleation/growth process.
Quantitative analysis of the particle height versus time also revealed a similar
nucleation and growth profile, including i) pre-spike, ii) pre-nucleation, iii) nucleation, and iv)
equilibrium growth (Figure 3.4d). During the pre-spike (i) and pre-nucleation (ii) phases,
heights of ~ 3 nm (115 pixel intensity) were observed and rapidly increased to ~ 4 nm (130140 pixel intensity) during the nucleation (iii) phase after which the height increase proceeded
more slowly during the subsequent growth (iv) phase (Figure 3.4d). Similar analysis of the
peptide area versus time showed that during the pre-spike phase (i) and pre-nucleation phase
(ii) the majority of peptides had an area of ~160-200 nm2, which then rapidly decreased (during
the nucleation phase) before levelling out to ~120-160nm2 in the equilibrium growth phase.
The latter can be explained by the increasingly number of newly formed species that have
smaller area, which significantly lowers the average area value per frame, compared to those
in the earlier pre-spike phase and pre-nucleation phases.
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Figure 3. 4. In-situ Aβ42 peptides nucleation process at pH 3. (a) HS-AFM Film strip shows the morphology of
Aβ42 diffusion on mica surface before the Spike (neutral condition, pH 7.4 20 µg/ml), nucleation stage between
spike and growth stage and the stable growth stage after the rapid nucleation process. Scale bar: 50nm. Imaging
rate: 2frame/sec. (b) Aβ42 peptide numbers distribution among different stages. (c) Surface roughness of Aβ42
on mica surface (d) Average height of Aβ42 peptides distribution (e) Average Size of Aβ42 peptides.

For comparison, similar experiments were conducted in alkaline condition at pH 11.
Figure 3.5a shows a filmstrip of different time points, including prior to the ‘spike’ (0 sec), the
spike (30 sec) and several subsequent frames out to ~380 sec.(supplementary Movie S20) Prior
to spike, fewer peptides were observed with a low surface density of ~10 molecules/um2 that
is consistent with the results shown in the imaging of ex-situ samples. After the spike, the
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surface density remained the same, with most of the existing peptides (black dash circle at
=133s) showing minimal surface diffusion. For the remainder of the imaging duration until to
383 sec, no other significant changes were observed. These observations were confirmed by
the subsequent analysis of particle count and r.m.s. surface roughness versus time (Figure 3.5b
and 3.5c). In these analyses, there was not change in their values post spike, referred to as the
stable phase (ii). The increase in surface roughness during the spike is artefact due to loss the
loss of imaging.

Figure 3. 5. In-situ Aβ42 peptides nucleation process in alkaline condition. (a) HS-AFM Film strip shows the
morphology of Aβ42 diffusion on mica surface before the Spike (neutral condition, pH 7.4 20 µg/ml), spike and
growth stage. Scale bar: 50nm. Imaging rate: 2frame/sec. (b) Aβ 42 peptide numbers distribution among different
stages. (c) Surface roughness of Aβ42 on mica surface.
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Further analysis of the dynamic nucleation and growth process at the single particle
level is shown in Figures 3.6 and 3.7. In particular, high resolution images of individual
molecules were captured and shown in Supplementary Movie S21, S22 and S23. Figure 3.6a-b
show representative filmstrips before and after spiking with the HCl, with individual particles
labelled (no.1-6) for the analysis. From 0-12 secs before the spike, three individual peptides
labelled 1-3 were observed to be diffusing freely on the mica surface (supplementary Movie
S19). This free diffusion phenomena last for 30 seconds until the spiking process, during which
the diffusion ability at 8.1 ±0.5 nm2/s is consistent with our previous work in neutral condition
(8.7 ± 0.44 nm2/s for Aβ15-20nm). After spiking these existing peptides (labelled 1-3) are
diffusing slower at ~5.8 ±0.36 nm2/s and during 64 – 84 sec in the pre-nucleation phase, there
is no significant observation though a few newly formed peptides appeared (Figure 3.6b).
During the nucleation phase at 154 sec, a significantly greater number of newly formed
peptides appeared, with those labelled from 4-6 selected for the analysis. Frames at later timepoints of 174 sec and 354 sec indicate that newly formed peptides (dash red circles) and
previously existing peptides (dash black circles) co-exist on the mica surface. Figure 3.6c-d
show zoomed in images of existing Aβ (3) and newly formed Aβ (5) as they increase in size
after spiking the sample with HCl. Additional analysis on the cross-section of individual
zoomed in peptides emphasized the dynamic changes on the lateral dimensions as well as the
height (Figure A4).
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Figure 3. 6. HS-AFM film strip shows the size and position changes of existing peptides appear all the time (dash
black circle number 1,2 and 3 as labelled) and newly formed peptides only appeared after the Spike (dash red
circle number 4,5 and 6 as labelled).

Kinetic traces of the area and height versus time of those individual peptides labelled
in Figure 3.6, including both newly formed and existing peptides, are shown separately in
Figure 3.7. For the existing peptides during the pre-nucleation phase (ii), there was significant
variation in the area growth rates (nm2/s) between the peptides (Figure 3.7a). For example, Aβ
(3) showed a faster growth rate (~1.50 nm2/s) followed by Aβ (2) (~0.71 nm2/s) whereas Aβ
(1) did not appear to increase in area. Beyond the pre-nucleation phase, the area of each peptide
effectively plateaued however some fluctuations in the values were still observed (Figure 3.7a).
Similarly, for heights of the same existing peptides (Figure 3.7b), equivalent profiles of the
traces were observed suggesting that the nucleation and growth is proportional in lateral (area)
and normal (height) directions, i.e. sphere-forming growth. For the newly formed peptides, Aβ
(6) appeared after nucleation stage phase (iii) and both the area and height increased during
equilibrium growth stage phase (iv) (Figure 3.7c and 3.7d). For the other two peptides, Aβ (4),
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Aβ (5), it was difficult to observe their initial growth during the nucleation phase (iii) though
small increases were observed in the height trace (Figure 3.7d). In the later growth phase (iv)
the traces plateaued though again showed fluctuations that we interpret as secondary nucleation
process.

Figure 3. 7. The tracking size and height of existing peptides and newly formed peptides. (a)(b) Representative
existing peptides of number 1,2 and 3 shows the size and height changes with the time growing. (c)(d)
Representative newly formed peptides of number 4, 5 and 6 shows the size and height changes with the time
growing.
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3.4 Conclusion
3.4.1 Factors in ex-situ: concentration, pH and incubation time
govern the aggregation of Aβ peptides
One of the key environmental factors believed to influence the Aβ aggregation process, leading
to toxic β-sheet rich oligomeric structures, is the pH [124, 320]. It is also proposed that Aβ
aggregation in the brain may occur in the lysosomal compartments where the pH is about 5.5 [363368]. Brain injury can also lower the local pH, which in turn may lead to AD [369]. Therefore,
understanding the effect of solution pH on the ability to initiate formation of oligomers and
aggregates is imperative. Previous AFM studies show that the amyloid aggregation and protofibrils formation are very pH-dependent. At neutral pH, Aβ peptides have limited solubility
and produce only spherical aggregates with predominantly β-sheet secondary structure,
whereas at acidic pH 4.9 formation of mature amyloid fibrils and proto-fibril can be observed
[370, 371]. Similarly, both the ex-situ and in-situ HS-AFM imaging shows that acidic
conditions significantly accelerate the peptide aggregation as opposed to alkaline conditions
that appears to have a minimal effect. In particular, in-situ imaging revealed that almost
immediately after spiking with HCl, the growth of existing peptides occurs followed by a rapid
nucleation event that produced mostly newly formed peptides.
These observations relate to a pH-driven protonation/de-protonation of Aβ residues,
previously shown to lead to a change in the net molecular charge from ~ -3 at pH 7 to 0 at
acidic pH [372]. Lowering the pH from 7.4 to 6.6 is also shown to reduce the zeta potential of
Aβ42 from -35 mV to -25 mV, respectively. Aβ1-40, has a pI at approximately pH 5.3 [320]
though is suggested to be only weakly charged until pH 9 (based on pKa analysis of individual
peptides) and becomes strongly charged at pH 12. For closely related Aβ42, the higher pH
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condition likewise increases charge on the monomer, resulting in the presence of stabilized,
soluble Aβ42 nanoparticles of size ∼50 nm [373]. Due to the presence of the mica surface, its
pH-dependent surface charge will also play a role in the nucleation and growth observed in the
in-situ HS-AFM imaging. Silanol groups of mica are assumed to control the pH-dependent
surface charge [374], giving a reduction in zeta surface potential [375] and weak attractive
forces at low pH (as opposed to long-range repulsive forces at higher pH) [376].
Therefore, we suggest that two general pH-drive mechanisms, based on the monomer
and mica substrate, enable visualization of nucleation and growth of the Aβ42 in Figure 3.4a.
Firstly, minimisation of mica surface charge at low pH will facilitate surface adsorption of the
monomer, which is interpreted as the appearance of the initial surface covering of Aβ42 at the
onset of the nucleation phase (Figure 3.4a, at 135 sec). In this and previous chapters, this effect
may also explain why monomers are not clearly observed at neutral pH, with only the preformed larger oligomers and aggregates present on the mica surface. The inability for the
monomer to adsorb to the surface at neutral pH would make them difficult to image and may
relate to the observation in the chapter 1 of the less well, structurally defined Aβ42 species that
transiently appeared in the HS-AFM movies and exhibited very fast diffusion (> 100nm/sec).
Once the monomer has adsorbed to the surface, minimization of its surface charge too, will
then facilitate the binding of additional monomers diffusing toward the surface, leading to
nucleation and growth. In addition, the charge minimization of the existing oligomers also
facilitate their continual growth during the pre-nucleation phase through to the subsequent
nucleation and growth phases.

3.4.2 In-situ amyloid nucleation process Aβ
Some of the earliest studies on nucleation and growth of amyloid beta fibrils describe that a
key factor in fibrillogensis was the spontaneous self-assembly of Aβ monomers into what were
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described as “micelles” of ~ 14 nm in size [374], or perhaps now more commonly referred to
as oligomeric structures. Specifically at low pH, these early models proposed mechanisms of
homogenous (primary) nucleation involving the self-assembly of monomers at a critical
concentration, or alternatively the heterogeneous (secondary) nucleation where the nucleation
process occurred on non-Aβ seeds, i.e. a substrate [374]. The homogenous (primary) nucleation
is a relatively simple model, intuitively providing a physical description of the aggregation
pathway and for most part is able to explain the macroscopically observed kinetics [375].
Similarly, such models propose that the rate-limiting step, causing the “lag-phase” in kinetic
growth studies, is due to the initial formation of nuclei that eventually become large enough to
grow spontaneously [376]. A consequence of adding a nucleus or “seeds” into a monomer
solution is a rapid aggregation process that can proceed without the need for priori nucleation
formation [377]. For example, the presence of undissolved small Aβ nanoparticles, or seeds,
or even a substrate surface, i.e. surface of the sample container, could initiate aggregation. This
underlies the mechanism of heterogeneous (secondary) nucleation, which was confirmed by
showing that the addition of “seeds” into a monomer solution caused a shortening of the lag
phase proportional to the seed concentration [104]. Hence, current descriptions of homogenous
(primary) nucleation involve the growth of individual nuclei through only monomer addition,
typically in bulk solution (homogeneous nucleation), while secondary nucleation occurs on the
surface of an existing amyloid structure, e.g. amyloid fibril, which “catalyses” the growth of
new nuclei. Elucidating such molecular pathways in which the toxic forms can be sequestered
or promoted are essential for potential therapeutic treatments. For example, Cohen et al. [315]
suggested a strong connection between the toxicity and the species produced from secondary
nucleation of monomers and this correlation further supported by in vitro studies indicating the
significant role of secondary nucleation in AD pathogenesis [104, 315, 378]. In particular,
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Meisl et al. [350, 379] found a saturation phenomenon of secondary nucleation occurred in
high concentration when the pH switched may also be involved in these combined processes.
Based on the above definitions, we interpret two processes of nucleation and growth of
the Aβ42 on the mica surface at low pH. Firstly, the observed growth of the existing oligomers
and aggregates follows a heterogeneous secondary nucleation process whereby monomers add
to existing “seeds” in the sample. This can be initiated immediately after a change in the
solution pH and predominately proceeds during the pre-nucleation phase (ii). Analysis of single
oligomer kinetics indicates that similar sized seeds can growth at different rates, typically in
the range of 0.71-1.5 nm2/sec and 0-0.71nm2/sec of area, for a duration of ~ 100 sec before the
growth plateaus. In addition, there is no observation of new seeds being released, or “buddingoff”, into the solution during this process, as has previously been described for catalysis of
nuclei from amyloid fibril surfaces [380] (shown in Figure 1.1a (chapter 1)). In contrast, the
catalysis of nucleating species via the mica substrate is representative of a heterogeneous
(secondary) nucleation process and appears to be initiated by a significant increase in peptide
surface adsorption at the beginning of the nucleation phase (iii) which lasts for ~ 30 secs. While
it is difficult to precisely determine when they first appear (due to resolution limit of AFM),
their growth rate and final dimensions are equivalent in range to those of the existing seeds.
Interestingly, many of the newly formed species could be observed diffusing on the surface
and interacting with each other, similarly to that shown in chapter 1, and in some cases
eventually form stable complexes. Hence, their diffusion can provide for subsequent
interactions between the different structural peptides such as peptides binding, elongation and
aggregation [381].
Lastly, pH-dependent structural formation of peptides has been revealed by a wide
range of methods including antiparallel β-sheet structure investigated by Solid state NMR [382]
and detection of aggregates by ThT [383]. Other emerging high resolution studies such as
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circular dichroism spectroscopy [384], flourier transform infrared spectroscopy [385] and Xray diffraction have also been demonstrated [386, 387].
While HS-AFM has previously revealed the dynamic growth of fibrils [221, 228, 388]
and binding of single oligomers/aggregates in our previous work [358], this is to our knowledge
the first time that Aβ nucleation and growth processes have been directly visualized at the
single molecule level. In doing so, we show that various pathways exist within the one system,
including nucleation of new species, growth of existing seeds, and formation of new species
through diffusion and binding - emphasizing the complexity of multiple microscopic processes
that potentially occur during a lag phase and lead to macroscopic differences in bulk
aggregation kinetics.
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Chapter 4: Molecular Interactions
between Aβ peptide and Silica
Nanoparticles Visualized by HS-AFM
4.1 Introduction
The abnormal generation of plaques comprising amyloid fibrils is central to pathological
diagnosis of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s
disease, type II diabetes and some types of cancers [389, 390]. For decades, extensive research
has been undertaken to investigate the underlying causes and explore potential therapies for
AD, yet unfortunately no effective treatments or drugs have successfully made it through
clinical trials. One issue is that very little is understood about the molecular mechanisms
through which the Aβ peptide induces the cytotoxicity. Up until recently, various structurally
distinct forms of Aβ aggregates, including oligomers and aggregated intermediates, have been
revealed as the toxic species [391-394]. Therefore, strategies that include the prevention or
interference of Aβ aggregation have become a significant focus in targeting the toxic species
and determining their role in the pathology of AD.
A large number of aggregation inhibitors have been explored as potential drug
candidates for directly targeting the Aβ formation. Traditional inhibitors can be generally
classified in two major groups, small biomolecules as binding partners of Aβ or peptides
including modified peptides and designer peptides. For example, three different casein kinase
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protein inhibitors were shown to decrease the amount of Aβ produced when interacting with
Aβ peptides [395, 396]. Some organic molecules such as the chelator, clioquinol, have also
been shown to inhibit fibrillization [397-402]. In addition, some designer peptides such as Aβ
KLVFF, iAβ5 and Aβ16-20e, which are derived from original fragments of protein have also
shown to inhibit fibril formation, and reduce the toxicity or disassembly of fibrils [403-406].
However, few of these inhibitors can be identified as potent clinical drugs due to their strong
side effects.
With the rapid development of nanomedicine, nanoparticles (NP’s) are becoming a
major cornerstone for drug delivery, molecular diagnostics, regenerative medicine and medical
imaging [407-411]. Thus, the interactions between nanomaterials and biomolecules have been
widely explored and shed light on how nanomaterials can be utilized in diagnostics and
treatments of disease. In particular, NP’s have attracted significant interest in AD therapies due
to their great adsorption capacity, ease of surface modification and ability to cross the blood
brain barrier [412, 413]. Multiple NPs, including polymeric [339, 341, 414-416], inorganic
[417-420], magnetic [421-423] and fullerene (carbon-based) [424-430] based particles have
demonstrated the ability to inhibit Aβ aggregation or fibrillation. Aggregation of Aβ in vitro
can be photo-thermally ablated through the short irradiation of Aβ peptide bound functionalised
gold particles [431-433]. Majzik.A et al. [434] revealed chain-like structures of Aβ aggregates
on gold nanoparticles decorated with cysteine- and LPFFD-OH, indicating that the
functionalized gold NP’s have significant effects on the conformation and structure of the
aggregates. Even as early as the late 90’s, fullerene (C60) derivatives were shown to have
neuroprotective properties by reducing neural cell death caused by Aβ peptide [424]. More
recently, fullerene nanoparticles were found to strongly inhibit the Aβ aggregation by
specifically binding to the central hydrophobic motif, KLVFF (16-20 residues, sequence of
amyloid beta ) of Aβ peptide [425]. Numerous other nanoparticles have been reported to be
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efficient at preventing Aβ peptide aggregation and reducing their cytotoxicity [414, 418, 432,
435-437]. For example, Ashwini S.Pai et al. [438] demonstrated the inhibitory effects of
(Polyethylene glycol) PEGylated phospholipid nanomicelles on the Aβ42 aggregation and
proposed this conventional nanomedicine carrier as a new potential therapeutic agent [438].
Fluorinated nanoparticles were shown to induce an α-helical structure in Aβ40, consequently
preventing fibril formation, while polymeric nanoparticles are also capable of blocking active
sites responsible for Aβ aggregation [339, 414]. Conversely, hydrogenated nanoparticles were
shown to accelerate β-sheet structure formation, leading to fibrillogenesis [439]. Similarly,
TiO2 nanoparticles have been found to promote Aβ aggregation by exhibiting a strong
adsorption capacity for Aβ peptide at high concentrations [440].
The underlying effects of NPs on Aβ aggregation, which is expected to be determined
by the NP’s composition and surface characteristics such as particle size, shape, surface charge
and modifications, remains largely unclear. Furthermore, evaluating kinetics of the Aβnanoparticle interactions, particularly at the single molecular level, also represents a challenge
[435]. For example, it is seemingly insurmountable to experimentally measure the kinetic rate
constant of a single Aβ-NP interaction within a complex mixture. Largely in the absence of
experimental data, molecular dynamics simulations have been widely used to reveal the
molecular mechanisms of interactions between protein and nanoparticles [441, 442]. Ding H
et al. [443] applied dissipative particle dynamics (DPD) simulations to investigate the effect of
protein adsorption on the delivery of nanoparticles. Coarse grained molecular dynamics
(CGMD) simulations have proven to be another powerful tool for the study of nanoparticles
interacting with biological systems, by which a growing number of simulation approaches
along with various proposed molecular modelling packages have been introduced. Slaven et al.
[444] utilized this method to investigate the effects of NPs on amyloid beta aggregation and
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found that the ratio of NP/proteins plays an important role in determining the aggregation
inhibition or promotion.
Despite the aforementioned molecular dynamic simulation approaches, experimental
tools with the ability to resolve both structure and dynamics at the molecular level are required.
This is where High-Speed Atomic Force Microscopy (HS-AFM) is beginning to address the
need for “structural-dynamics” by enabling direct visualization of label-free single molecules,
with imaging speeds of 10-20 frames per second (fps) in liquid [207, 221]. While HS-AFM has
previously been used to reveal dynamics of Aβ fibril formation and oligomeric intermediates,
including our work on intra-molecular binding kinetics between different types of Aβ
oligomers and aggregates [221, 228, 230, 358], this study to our knowledge is first to report on
the dynamics of Aβ-nanoparticle interactions, and more generally the nanoparticles themselves.
HS-AFM was employed to characterize the structural information and dynamics of silica
nanoparticles (LUDOX HS-40 colloidal silica), followed by a co-deposition with Aβ42 peptides
to investigate SiNPs-Aβ interactions. We applied the single molecule kinetic analysis
established in the previous chapter, which is based on image contrast in HS-AFM movies, to
understand the Aβ-nanoparticle interactions. The applicability and considerations of the
analysis, particularly when measuring interaction kinetics in the presence of a substrate is
discussed.
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4.2 Materials and Methods
4.2.1 Preparation of Aβ42 and Silica Nanoparticle Samples
LUDOX HS-40 colloidal silica (12nm diameter), amyloid-beta protein fragment 1-42 (Aβ42
peptide) were purchased from Sigma-Aldrich. The silica-nanoparticle solution was prepared as
40wt % in water and then 100ml silica-nanoparticle solution was diluted to 20wt% in 50ml
PBS solution prior to use. Aβ42 peptide solution was prepared by dissolving 1mg lyophilized
solid peptides into HFIP to prevent the aggregation and then aliquot into 50 small
microcentrifuge tubes. After half an hour incubation at room temperature in a chemical fume
hood, the HFIP was allowed to evaporate for 60 minutes and the re-lyophilized peptides stored
at -20°C. Aqueous solutions were prepared by dissolving peptides into PBS (PH 7.4) at
concentration of 20 µg/ml and then vortex mixed for 20 sec prior to use.

4.2.2 HS-AFM Imaging/ Data analysis
To prepare samples for HS-AFM imaging, 2 µl of the silica nanoparticle solution was pipetted
onto a 1.5 mm diameter freshly cleaved mica disc (Cat No. 7101) and incubated for 2 minutes
to allow the particles to adsorb onto the mica surface. 2 µl of fresh PBS was then added and
pipetted in/out of the sample solution, and this was repeated several times to exchange the
sample solution in order to remove excess particles that had not adsorbed onto the mica surface.
The sample was then placed into the liquid cell of the HS-AFM and imaging was performed
(Research Institute of Biomolecule Metrology Co., Ltd., Japan) in tapping mode with high
frequency, small cantilevers (BL-AC10, Olympus) remodified with the carbon-tip, as
described above. For experiments involving co-deposition and imaging of both the silica
nanoparticles and Aβ42, stable HS-AFM imaging of the silica nanoparticles was firstly
achieved, as described above. Following this, 10 µl of a 1 µg/ml Aβ42 peptide solution was then
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injected into the liquid cell and further mixed by pipetting in/out whilst continuing imaging of
the silica nanoparticles. This injection of the Aβ42 solution and mixing typically perturbed or
caused a loss of the imaging, e.g. the tip lifts of the surface, though stable imaging could easily
be reattained after optimization of the feedback gains, set point and amplitude. During imaging,
the free oscillation amplitude of the cantilever was set to ~2 nm and the set point amplitude
was kept to ~ 90% of the free amplitude. The maximum possible scanning rate is calculated as
Rmax= (λƒ)/(2WN), where λ is the amplitude, ƒ is feedback bandwidth, W is the scanning size
and N is the number of corresponding scan lines. A non-electrode wide scanner with range of
4 μm * 4 μm and z scanner (700 nm) with scan speeds of normally 1-4 frames/sec for 500 nm
scans was used. For higher resolution scans of 200 nm, 5-10 frames/sec with 550-275 lines/sec
was applied.
Data analysis of the values obtained from the Matlab software was investigated as mentioned
in Chapter 2.
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4.3 Result and Discussion
4.3.1 Silica nanoparticles (SiNP)
HS-AFM movies were taken at 1 frame/sec with 500nm scan size to visualize the silica
nanoparticles in phosphate buffer solution on a mica substrate. A representative single frame
reveals the silica nanoparticles exhibit a degree of size variation (e.g. some larger aggregates
are present), with surface density of ~100-120 NP’s/µm2 (Figure 4.1a). Corresponding movies
show the surface diffusion of these nanoparticles, including dynamic, physical interactions
occurring between individual NP’s where they are observed to come into contact for various
periods of time (typically on the order of seconds) and then separate or diffuse away
(Supplementary Movies 24 and 25). High resolution images show the NP’s mostly have a
spherical morphology though also appear to assemble or aggregate into various string-like
morphologies (Figure 4.1f). Statistical analysis of the NP dimensions was obtained from
Matlab software designed to segment imported (movie) AVI.file into individual frames,
automatically detect all objects, and analyse parameters such as XY coordinates, eccentricity,
perimeter, area, height (pixels intensity), width and length. Histograms of the area showed two
distinct peak distributions (Figure 4.1b), including the most abundant NP’s with area of 105 ±
36.8 nm2 and a smaller distribution at 520 ± 48.4 nm2 that is indicative of aggregated NP.
Histograms of the length and width (Figure 4.1d, e) showed peak distributions of 12.9 ± 3.2
nm and 11.0 ± 2.7 nm, respectively, confirming spherical NP with effective diameters
correlating to the nominal size of ~12nm for these commercially available SiNPs (Ludox HS
40). A smaller sampling of larger widths at ~30 nm was observed (Figure 4.1e), presumably
related to the aggregated NPs. Similarly, analysis of the height gave two peak distributions at
2.1 ± 0.9 nm and 5.8 ± 1.1 nm correlating to the main and aggregated NP’s (Figure 4.1c).
However, the NP height was significantly lower than the expected NP size (12 nm) [445, 446],
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indicating an imaging artefact causing an underestimation of the actual height. Normally tip
broadening can overestimate the lateral dimensions though anomalies in z-height are also
reported and previously shown to be due to frequency shift in response to tip-sample interaction
when imaging nanoparticles in tapping mode [447].

Figure 4. 1. Morphology and structural dimensions of Silica Nanoparticles. (a) Representative HS-AFM image
of Silica Nanoparticles diffuse on the surface of mica. (Scan scale: 500*500nm, imaging rate: 1frame/second)
Histograms of different structural dimensions distributions Area (b), Height (c), Width (d) and Length (e) of Silica
Nanoparticles.(f) Spherical and string morphology of various structural silica nanoparticles.

4.3.2 Imaging of Co-deposited SiNP - Aβ42
HS-AFM imaging was performed on samples comprising both SiNP and Aβ42 on the mica
surface in PBS. In these experiments, SiNP were first deposited on the surface and stable
imaging achieved at 1 frame/sec, as performed above for their analysis in Figure 4.1, prior to
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then injecting a small volume (10 µl) of a 1ug/ml Aβ42 solution. Two representative examples
of movie filmstrips show the time-course of the experiments from 0-500 sec, including the
initial frame of only SiNPs (defined as 0 sec), injection or ‘spiking’ with Aβ42 at 170 sec,
followed by imaging of SiNP and Aβ42 coexisting on the surface until 500 sec (Figure 4.2).
Corresponding movies are given in Supplementary Movies 26 and 27. Immediately after
spiking with Aβ42 peptide, the perturbation caused by injecting the solution caused instability
in the imaging, i.e. lifting up of the cantilever tip from the surface, resulting in loss of imaging
(Figure 4.2, at 170 sec). In this case, the imaging set-point was readjusted to resume stable
imaging typically within < 30 sec. Beyond this point from 200 – 500 sec duration, it was evident
that an increasing number of Aβ42 peptides appeared on the surface.

Figure 4. 2. HS-AFM film strips shows the morphology of silica nanoparticles diffusion on mica surface before
the Spike and the co-existing phase of nanoparticles and peptides after Spike. Scale bar: 50nm. Imaging rate:
1frame/sec.

To confirm the qualitative observations in Figure 4.2, analysis of both the object count
in each frame and root mean square (r.m.s.) surface roughness versus imaging time is shown
in Figure 4.3. Prior to spiking with Aβ42, the object count only represented the number of SiNPs
in each frame, which reached a constant value ~20-25 NP’s per frame (Figure 4.3a, NP’s (i)).
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After spiking, the object count significantly increased to a combined ~30-40 NP’s-Aβ42 per
frame (Figure 4.3a, NP’s + Aβ42 (ii)), indicating the addition of the Aβ42 on the mica surface.
Similarly for the r.m.s. roughness, an increase in value from 0.7 nm before spiking to 0.9 after
spiking indicated an increasing number of Aβ42 adsorbing to the mica surface (Figure 4.3b and
4.3c). Despite confirming the co-existence of the SiNP- Aβ42, qualitatively distinguishing them
from each other directly from the movies was difficult due to their similar morphology and size.
Hence, further analysis was undertaken to compare their size dimensions and diffusion speed.

Figure 4. 3. In-situ spiking process that silica nanoparticles interacting with Aβ42 peptides. (a) Numbers
distribution of Silica nanoparticles co existing with Aβ42 peptides among different stages. (i) Only silica
nanoparticles, (ii) silica nanoparticles and Aβ42 peptides.(b) Surface roughness of silica nanoparticles on mica (c)
Surface roughness of silica nanoparticles with injected Aβ42 peptides.

Histogram analysis of area, height, length and width was performed on the co-deposited
SiNP- Aβ42 samples on frames within the first 5 min and also after 30 min of spiking with Aβ42
(Figure A5 and A6). From these histograms, the peak distribution values (represent the values
of main species at different stages) with errors (e.g. width of Gaussian fit) are compared (Figure
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4.4d-g) along with their representative images at 0 sec (NP’s only), and 5 min and 30 min after
spiking, in Figure 4.4a-c. Firstly, object detection from the images (Figure 4.4a-c) indicated an
increasing number of Aβ42 after spiking, with values reaching ~30-45 NP’s/ Aβ42 per frame
and ~45-70 NP’s/ Aβ42 per frame after 5 min and 30 min, respectively (Figure A5 and A6).
After 5 min, the peak value for area (Figure 4.4g, blue bar) reduced to 80 nm2 compared
to 105 nm2 for the NP’s only, while a slight decrease in values also occurred for length (12.1
nm) and width (10.1 nm) however these decreases in the dimensions of the co-deposited SiNPAβ42 were not statistically significant. In contrast, a corresponding increase in height to 2.8 nm
(Figure 4.4f, blue bar) suggests that interactions such as possible adsorption of Aβ42 onto SiNP
and/or rearrangement of their conformation may be involved. After 30mins, the peak
distribution values for area, length and width, show an increase in values (Figure 4.4, magenta
bar) compared to both the NP’s only and NP’s-Aβ42 after 5 min. The exception was height
which remained equivalent and was not statistically different. For comparison, the dimensions
of the most abundant Aβ (Aβ15nm) obtained previously in Chapter 2 are also included in Figure
4.4 (red bar) and indicate that the Aβ15nm oligomer is similar in height but has significantly
greater lateral dimensions. This analysis shows that individual Aβ and SiNP have a distinct
size difference, with the Aβ of ~ 15-20 nm and SiNP of ~ 12 nm that closely matches its
commercially reported value. However, analysis of co-deposited NP’s-Aβ42 reveals the size is
more equivalent to the SiNP, with no distinct separate distributions observed in the histograms.
Thus, distinguishing between the two NP and Aβ immediately after co-deposition was difficult.
After 30 min, there appeared to be an increase in NP’s-Aβ42 size, suggesting either their binding
or aggregation though the size remained smaller than the Aβ only.
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Figure 4. 4. Statistical analysis before and after the spike. (a)(b)(c)Representative snapshots of HS-AFM showed
pure silica nanoparticles on mica and silica nanoparticles co existing with amyloid-beta peptides. Dimensions
comparison among peptides, silica nanoparticles and co existing complexes. (d)(e)(f)(g) represent for Length,
Width , Height and Area respectively, errors are standard deviation. The numbers of molecule calculated for the
bar graphs are at least 25 molecules each frame for single measurement, though the numbers will reach to around
75 for the total three separate measurements.

4.3.3 Diffusion of SiNP and Aβ Comparison
To quantify surface diffusion, individual SiNPs were tracked (n=30) in Matlab software and
analysis of mean square displacement (MSD) of single SiNPs as a function of time was plotted
(Figure 4.5a). In addition, the different sizes of the SiNPs are indicated in Figure 4.5a to assess
the effect of particle size on the surface diffusion, revealing that surface diffusion decreased
(lower MSD slopes) with increasing SiNP size (Figure 4.5a). (Table 4. 1) In the calculated
diffusion coefficient, this effect was observed as an exponential decrease in the diffusion
coefficient with increasing particle size, indicating a particle-size dependency that may be due
to a direct effect (molecular size) or indirectly by influencing the particle-surface interactions,
e.g. due to change in particle-surface contact area. In particular, it was found that, irrespective
of particle size, the diffusion range of ~0.6 – 5.8 nm2/s for SiNP was significantly slower than
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the diffusion of similar sized Aβ42 oligomers (~8.3 - 9.2nm2/s) but faster than the larger Aβ42
aggregates (~0.4 nm2/s) measured in the previous chapter 2.

Figure 4. 5. (a) Mean square displacement (MSD)verse time plot of individual tracked nanoparticles with different
size. MSD=<|r(t)-r(0)|2>, where <> means the average, r(t) is the position of each particle in determined time t,
r(0) stands for the reference spot of each particle. n=> 30. Black line represents for the size of particles is less
than 12nm, red line shows particles range with 12-18nm and blue line stands for particles larger than 18nm. (b)
Diffusion Co-efficient scatters of different size particles fitted by nonlinear curve fit (red line for Asymptotic1
fitting).

Based on previous analysis established in Chapter 2 for quantifying single molecule
kinetic parameters for Aβ - Aβ binding, we applied the same analysis to single SiNP–SiNP
interactions in samples with SiNP only. A representative filmstrip (5 frame/sec) showing the
analysis process is shown in Figure 4.6a and 4.6b, with the corresponding movie given in
Supplementary Movie S28. Starting at time = 0 sec, three SiNPs of varying size (labelled 1, 2
and 3) are observed to be freely diffusing on the mica surface. After 0.2 sec, SiNP (1) attaches
to a larger SiNP (2) and both remain as a complex (1+2) until time point 1.0 s. During this
period, the complex (1+2) increases in both width and length, and exhibits slower surface
diffusion. SiNP(1) then dissociates from SiNP (2) and diffuses away at 1.0 sec but then
undergoes binding (SiNP(1+2) at 1.4s) and dissociation again (1.6s). Subsequent SiNP-SiNP
interactions did not occur again until timeframe 8.8 - 34.4s (Figure 4.5b). During this period, a
new SiNP (4) entered the scan area (8.8s) and interacted with SiNP (3) (10 sec), undergoing
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initial ‘binding’ and then unbinding until 32.6s. By measuring the amount of time the two
SiNPs spent in physical contact, as demonstrated by ‘on’ or ‘off’ in Figure 4.6c, lifetime
distributions could be produced to extract kinetics parameters such as mean lifetime<t>,
binding rate Kon and dissociation rate Koff (Figure 4.6d). Exponential decay functions fitted to
lifetime distributions gave a mean lifetime of <t>=4.55 sec, with Koff of 1/<t>=0.22s for the
interaction between SiNPs (Figure 4.6d). Importantly, the relationship between the SiNP size
and the time ‘on’ for binding is shown in Figure 4.5e, (Table 4.2) which indicates an increasing
exponential-like relationship. Hence, the latter is inversely correlated to the size-dependence
of the diffusion coefficient in Figure 4.5b, indicating that the kinetic parameters are directly
influenced by the surface diffusion of the SiNP. The implications of this on the HS-AFM
analysis of interactions are discussed further below.

Figure 4. 6. Dynamics and Interactions between silica nanoparticles.(a)HS-AFM film strip showed binding
processes between a small particle (no.1) and a relative large one(no.2).(b)HS-AFM filmstrip showed
representative interaction processes between two similar size particles. Scale bar:25nm, 5frames/sec. (c) A
representative figure showing the time ‘on’and ’off’ state, where number 1 refers to a binding state while number
0 refers to an unbound state. (d)Lifetime distributions for the bound state of particles with size range around
12nms. Distribution is fit to a single exponential decay (e) The binding time ‘on’ within the interactions versus
the size of active nanoparticles. Distribution is fit to a polynomial order 2 curve.
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4.3.4 Interactions and Kinetics of Co-deposited SiNP - Aβ42
As demonstrated from the previous chapter, the Aβ42 peptides were observed to diffuse
significantly faster than the SiNP (cf. ~8.3 - 9.2nm2/s versus ~0.6 – 5.8nm2). To confirm this
observation in samples comprising the co-deposited SiNP and Aβ42, individual objects with
sizes ranging from ~ 10nm to 20 nm were individually tracked for > 200s to calculate their
diffusion coefficients. The average coefficient was found to be 2.05 ±0.04nm2/s (Figure 4.7a),
which was higher than the pure SiNP (0.46 ± 0.01nm2/s) but much lower than the Aβ42 only
(7.95 ±1.99nm2/s (Figure 4.7a). Importantly, two different distributions of diffusion coefficient
were observed within the same size range (Figure 4.7b), suggesting that delineation of separate
SiNP and Aβ42 diffusion speeds within the co-deposited sample. Therefore, despite their similar
dimensions, it was possible to identify either SiNP or Aβ42 based on their diffusion speed,
especially since the diffusion of Aβ42 exhibited close to 16 times faster speeds than SiNP.
Having the ability to identity the SiNP and Aβ42, the same kinetic analysis was used to quantify
single molecule kinetics of SiNP-Aβ42 interactions, with a representative filmstrip at 2
frame/sec shown in Figure 4.7a. (Supplementary Movie S29) At time 0 sec, a single Aβ42 (1)
(green circle) was observed to freely diffuse and then bind to a SiNP labelled (2) (red circle) at
2.5 sec to form a complex (1+2) that increases in height. In subsequent frames, the complex
(1+2) undergoes repeated dissociation and rebinding. Table 4. 3 shows a list of 20 different
SiNP-Aβ interactions that were analysed from the HS-AFM movies, with corresponding values
of size and diffusion coefficient given for each SiNP and Aβ participating in the interaction.
Analysis of time ‘on’ for binding and exponential decay fit to lifetime distribution in Figure
4.7d gave a mean lifetime<t> at 1.15s and Koff of 0.87s, indicating that affinity between Aβ42
– SiNP interactions was significantly weaker than the interaction between two SiNPs. However,
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as mentioned above, due to the apparent dependence of binding lifetimes on the particle size
and/or diffusion the implications of this analysis are discussed further below.

Figure 4. 7. Dynamics and interactions between silica nanoparticles and peptides.(a)Representative HS-AFM
filmstrip shows the process between single Aβ42 peptide and nanoparticle. Scale bar: 25nm. Scan
rate :2frames/sec. (b) Diffusion Co-efficient of silica nanopartilces and Aβ42 peptides with similar size. Green
(Aβ42)and red (Nps)lines are fit by nonlinear curve fit (Asymptotic1).(c)Comparison of the diffusion ability
among single nps, Aβ42 peptides and the mixture of both. Average diffusion co-efficient of 0.46±0.1 nm2/s
(nps),7.95±1.94 nm2/s (Aβ42)and 2.05±0.4 nm2/s (mixture).Errors are standard deviation. N=>20
molecules.(d)Lifetime distributions for the bound state between particles and Aβ42 peptides with similar size
around 12nms. Detailed information is shown in Table 4. 1.

136

4.4 Conclusion
Understanding the diffusion of nanoparticles in fluids is important for a wide range of
therapeutic applications, for example in drug delivery, with typical diffusion coefficients for
nanoparticles on the order of 10e-12 m2/s (1000 *104 nm2/s) . Ellina A. M et al. [448] have
detailed the effects of particle size, medium viscosity and components of the liquid medium on
nanoparticle diffusivity. For example, silica nanoparticles coated with polyethylene glycol
exhibit an enhanced diffusion of 906 ± 89 *104 nm2/s in water, while thiolated nanoparticle
diffusion decreases to 731 ± 40*104 nm2/s, even though their particle sizes are similar. This
nanoparticle diffusion is however very different to those conditions under which the HS-AFM
is operated, namely due to the presence of a solid substrate that clearly hampers the nanoparticle
diffusivity. In the vicinity of the mica substrate, the calculated diffusion coefficients of both
Aβ42 and SiNP in this study and previous chapters are on the order of 1-10 nm2/sec,
approximately six orders of magnitude lower than nanoparticles allowed to “freely” diffuse in
liquid [448, 449]. Previous work on single particle tracking of individual proteins (RAD54) on
mica and MSD analysis using HS-AFM have revealed similar coefficients of ~ 2 nm2/sec and
likewise noted the discrepancy with reported diffusion coefficients of 96 ± 89 *106 nm2/s for
globular proteins in water. Accordingly, reduced diffusion associated with surface interactions
can be explained by physical adsorption theory [450] whereby weak adhesion forces, such as
the Van der Waals forces between the particle and surface, affects the surface driven Brownian
motion.
In the previous chapter 1 Aβ15-20nm  Aβ15-20nm interactions gave a mean lifetime <t>
= 0.55 ± 0.22 sec (koff (1/<t>) = 1.82 sec-1) compared to the Aβ15-20nm  Aβ36nm with a mean
lifetime = 0.72 ± 0.28 sec (koff = 1.39 sec-1), indicating that interactions with the larger-sized
Aβ36nm form a more tightly bound complex due to the slower dissociation rate (lower koff ).
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Nevertheless, it was clarified that a slower dissociation rate could be partially governed by
diffusion, as the slower diffusing Aβ36nm on the mica surface may influence the time it spends
in contact with another peptide, i.e. it take longer to diffuse away and hence a longer time “on”
will be recorded in the HS-AFM analysis. Similarly, in the previous chapter 1, the largest Aβ
aggregate, AβAgg, had an order of magnitude lower diffusion coefficient than both the Aβ15-20nm
and Aβ36nm, and hence so too may influence the binding lifetime. Furthermore, in this chapter,
it was clearly evident that increasing SiNP particle size caused a decrease in diffusion (Figure
4.6e) but also conversely an increase the binding lifetime (time “on) (Figure 4.7d), suggesting
that differences in particle size influence diffusion which in turn affects the measured time “on”
or binding lifetimes.
When considering the aforementioned effect of diffusion, we conclude that caution
must be taken when assessing kinetic parameters based on the HS-AFM analysis. For example,
the lower Koff value of the SiNP-SiNP interaction indicates a longer bound-state compared to
the SiNPs-Aβ42 peptide interaction. However, the slower diffusivity of the SiNPs could
contribute to their lower Koff, as explained above. Similarly, the lower Koff of both SiNP-SiNP
and SiNP- Aβ42 interactions compared to Aβ42- Aβ42 interactions measured in the previous
chapter (with the exception of the larger Aβ42 aggregate) possibly result from the slower SiNP
diffusion and/or faster Aβ42 diffusion. One other observation is that while the time “on”
exponentially increases with particle size, the effect did not occur until the particle size reached >
12-13nm, suggesting that analysis of smaller particles in Figure 4.6e may differ from larger
aggregates. Despite this, at this early stage in development of HS-AFM for analysis of single
molecule or nanoparticle interactions the effect of particle diffusion on the kinetic analysis
needs to be further investigated.
In light of above, there are still aspects of the kinetics analysis that cannot be explained
by diffusion. For example in the previous chapter, while the diffusion ability of different sized
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Aβ15-20nm and Aβ36nm species was significantly different by ~8 times, the binding lifetimes were
similar, e.g. 0.55 ± 0.22 sec and 0.72 ± 0.28 sec for Aβ15-20nm and Aβ36nm, respectively.
Additionally, as mentioned above, the AβAgg diffuses significantly slower compared to the
Aβ15-20nm and equivalent to the Aβ36nm. Yet under these conditions, the AβAgg shows a
“stochastic” lifetime of binding that cannot be explained by its lower diffusion. From these
findings, further investigation is required to validate the HS-AFM analysis of binding kinetics.
It is suggested through appropriate experimental design that binding kinetics could be analyzed
by 1) keeping one particle fixed and the other freely diffusing, 2) using a nanoparticle substrate
rather than freely diffusing nanoparticles and 3) controlling the surface diffusion of particles
by modifying the surface.
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Table 4. 1. Individual silica nanoparticles interactions
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Table 4. 2. Table for silica nanoparticle binding associated with size
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Table 4. 3. Table for interaction between peptides and silica nanoparticles
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Chapter 5: Conclusion and Outlook
5.1 Conclusions
The structural characterization and dynamics interactions between Aβ42 peptides were
investigated by High Speed Atomic Force Microscopy, which is capable of directly
visualization of single molecules and proteins at sub-nanometre structural level with
millisecond temporal resolution in liquid. Analysis of dimensions revealed up to three main
Aβ42 species distributions, Aβ15-20nm, Aβ36nm and Aβagg, in addition to the appearance of fast
diffusive monomers when compared to the larger Aβ42 species. Prior to the peptides interaction
analysis, quantitative measurement of molecular diffusion was also conducted by tracking
individual molecules with the designed software Mat-lab and the results showed the mean
square displacement (MSD) have a linear dependence relation with the molecule size, with 8.7
±0.44 nm2/s, 1.1 ±0.06 nm2/s and 0.4 ±0.01 nm2/s for Aβ15-20nm, Aβ36nm and Aβagg respectively.
Additionally, the relationship between different parameters also suggested a potential model
for the peptide assembly, which is termed as combined lateral additional elongation step with
height stacking process.
Significantly, we established a new platform based on image contrast in the captured
videos to quantify reaction rate determining kinetics constants for interactions between
different Aβ42 species. The results showed that interaction between smaller Aβ15-20nm to Aβagg
followed by a type of kinetic heterogeneity with the lifetime at 2.04s while the lifetime for
Aβ15-20nm -Aβ15-20nm and Aβ15-20nm to Aβ36nm are very short and both fit to a single exponential
decay, with 0.55s and 0.72s respectively, indicating significant different pathways for
interactions between different species to overcome the energy barrier and the complexity of
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various structural aggregates will hinder the advancement on the Aβ toxicity identification and
proper targeting.
Different environmental factors such as peptide concentration, incubation time and
solution pH were investigated under ex-situ conditions by HS-AFM. The results indicated that
the effect of peptide concentration and incubation time on the structural morphology and
diffusion of peptides was minimal, however, a decrease in solution pH accelerated the
formation of toxic β-sheet rich oligomeric structures. Further in-situ HS-AFM imaging of this
pH-induced aggregation process was able to observe the real-time nucleation and growth of
single Aβ, including elucidating distinct separate pathways leading to formation of Aβ
oligomers.
Having characterized the Aβ42 peptide, silica nanoparticles were introduced to
investigate their interactions with the peptide. The silica nanoparticles (SiNPs) were found to
be 12nm in diameter and exhibited significantly slower diffusion (coefficient at 0.46 ± 0.1
nm2/s) compared to similar sized Aβ42 peptides (7.95 ± 1.94 nm2/s). In samples co-deposited
with SiNP and Aβ42 it was difficult to distinguish them based on size, though clear difference
in their diffusion enabled their identification for further analysis. Subsequently, kinetic analysis
of real-time interactions between SiNPs and peptides showed that the particle size had a
significant effect on diffusion, which in turn influenced determination of binding lifetimes in
the kinetic analysis. Hence, further investigation on the effects of diffusion on the kinetic
analysis at single molecule level is still needed.
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5.2 Outlook
Protein aggregation is believed as a highly complex problem at molecular level, with little
clarity around the kinetic mechanisms [451]. Despite the extensive literature, currently there is
much more to be understood on the processes of aggregation, including nucleation,
polymerization, elongation and fibrillation [452]. Also, many hypothesises of the amyloid beta
aggregation lacks a precise definition on molecular kinetic equation due to the mathematical
complexity [112]. Therefore, there is a disconnect between the fundamental parameters such
as the transient rate constants or structural dimensions and corresponding species due to these
confused nomenclature.
It has been widely demonstrated that prefibrillar assemblies of amyloid peptide, such
as soluble oligomers or protofibrils, instead of mature end-stage amyloid fibrils are the main
toxic species in protein misfolding diseases [59]. However, the pathway(s) by which normal
monomeric forms of the peptide become intermediates or fibrils that are associated with
toxicity is still uncertain. In this case, approaches based on in vivo cell culture experiments to
assess the toxicity of structural intermediates, for example the oligomers and aggregates
identified by HS-AFM could be useful. Similarly, assessing toxicity of samples based on a
priori characterization of molecular forms of Aβ could also be applied more generally to the
problem of protein aggregation. Elucidating the structure and associated toxicity will provide
a fundamental basis for development of potential targeting via therapeutic drugs.
Lastly, as an alternative to antibodies and other chemical compounds [453, 454], nanomaterials
such as the carbon nanomaterials [455, 456] have been shown to have inhibitory/promoting
effects on the protein aggregation. In addition, the combination of these two classes of materials
is believed as a compromising way to assess or control the cytotoxicity due to their
dispersibility in liquid. Therefore, the diversity of these nanomaterials and protein forms may
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bring a tremendous potential for both structural and dynamic characterization requirements.
The application of HS-AFM imaging with single molecule dynamic analysis will then provide
unprecedented opportunity to elucidate a wide range of molecular interactions [457].
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Chapter 6: Appendix

Figure A1. Length histogram of the Aβ peptides. we have an inset figure specifically for the length
greater than 40nm to illustrate that some unstructured species normally have transient structure with
unique higher values of ~up to 100nm.
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Figure A2. AFM cross-sectional analysis show how we track the dynamics and measure the structural
dimension of these less well structured Aβ42 species.
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Figure A3. Relationship between length and width shows a linear correlation.
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Figure A4. Image line profile of cross-section on individual molecules. Represent three single peptides
appearing on mica surface and present dynamic changes on the lateral dimensions as well as the height.
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Figure A5. Morphology and structural dimensions of Silica Nanoparticles and amyloid-beta42 peptides
injection during the first five minutes. (a) Representative HS-AFM image of Silica Nanoparticles and
peptide diffusion on the surface of mica. (Scan scale: 500*500nm, imaging rate: 1frame/second)
Histograms of different structural dimensions distributions Area (b), Height (c), Width (d) and Length
(e) of Silica Nanoparticles and peptides.

Figure A6. Morphology and structural dimensions of Silica Nanoparticles and amyloid-beta42 peptides
injection after 30 minutes. (a) Representative HS-AFM image of Silica Nanoparticles and peptides
diffuse on the surface of mica. (Scan scale: 500*500nm, imaging rate: 1frame/second) Histograms of
different structural dimensions distributions Area (b), Height (c), Width (d) and Length (e) of Silica
Nanoparticles and peptides
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S 1. HS-AFM movie of Aβ42 species diffusing on the mica surface. Scan size 500*500nm, scan rate 2frame/sec.
*5 video playing speed.
S 2. HS-AFM movie of Aβ42 species fast diffusing and capturing transient structured species.
S 3. HS-AFM movie of Aβ15-20nm diffusing and tracking processes. Dash line refers to the original position and
solid line represent the current position.
S 4. HS-AFM movie of Aβ36nm diffusing and tracking processes. Dash line refers to the original position and solid
line represent the current position.
S 5. HS-AFM movie of Aβagg diffusing and tracking processes. Dash line refers to the original position and solid
line represent the current position.
S 6, HS-AFM movie of whole processes of dynamic interactions between different Aβ species. The mechanism
that elongation and stacking of the peptides assembly also revealed during the process.
S 7. HS-AFM movie of interaction process between Aβ15-20nm and Aβagg. Dash line refers to the original position
and solid line represent the current position.
S 8. HS-AFM movie of interaction process between Aβ15-20nm and Aβ36nm. Dash line refers to the original position
and solid line represent the current position.
S 9. HS-AFM movie of interaction process between Aβ15-20nm and Aβ15-20nm. Dash line refers to the original
position and solid line represent the current position.
S 10. HS-AFM movie of 50 µg/ml Aβ42 species diffusing on the mica surface. Scan size 500*500nm, scan rate
2frame/sec.
S 11. HS-AFM movie of 100 µg/ml Aβ42 species diffusing on the mica surface. Scan size 500*500nm, scan rate
1frame/sec.
S 12. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after 2hours incubation in pH 7.
Scan size 500*500nm, scan rate 1frame/sec.
S 13. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after 4hours incubation in pH 7.
Scan size 500*500nm, scan rate 1frame/sec.
S 14. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after 1hours incubation in pH 3.
Scan size 500*500nm, scan rate 1frame/sec.
S 15. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after 1hours incubation in pH 11.
Scan size 500*500nm, scan rate 1frame/sec.
S 16. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after 2hours incubation in pH 3.
Scan size 500*500nm, scan rate 1frame/sec.
S 17. HS-AFM movie of 10 0µg/ml Aβ42 species diffusing on the mica surface after 4hours incubation in pH 3.
Scan size 500*500nm, scan rate 1frame/sec.
S 18. HS-AFM movie of 100 µg/ml Aβ42 species diffusing on the mica surface after 20hours incubation in pH 3.
Scan size 500*500nm, scan rate 1frame/sec.
S 19. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after spike, inducing decreased
solution pH from 7.0 to 3.0. Scan size 500*500nm, scan rate 1frame/sec.
S 20. HS-AFM movie of 20 µg/ml Aβ42 species diffusing on the mica surface after spike, inducing increased
solution pH from 7.0 to 11.0. Scan size 500*500nm, scan rate 1frame/sec.
S 21. HS-AFM movie of no.3 peptide nucleation processes after spike. Scale bar 20nm. Scan rate 5frames/sec.
S 22. HS-AFM movie of no.4 peptide nucleation processes after spike. Scale bar 22nm. Scan rate 5frames/sec.
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S 23. HS-AFM movie of no.5 peptide nucleation processes after spike. Scale bar 18nm. Scan rate 5frames/sec.
S 24. HS-AFM movie of silica nanoparticles diffusing on mica. Scan size 500*500nm, scan rate 1frame/sec.
S 25. HS-AFM movie of silica nanoparticles diffusing on mica. Scan size 500*500nm, scan rate 1frame/sec.
S 26. (1)(2) HS-AFM movie of in-situ interactions between silica nanoparticles and injected Aβ42 peptides. Scan
size 500*500nm, scan rate 1frame/sec.
S 27. HS-AFM movie of in-situ interactions between silica nanoparticles and injected Aβ 42 peptides. Scan size
500*500nm, scan rate 1frame/sec.
S 28. HS-AFM movie of single molecular interactions between silica nanoparticles. Scan size 250*150nm, scan
rate 5frames/sec.
S 29. HS-AFM movie of single molecular interactions between silica nanoparticles and Aβ 42 peptides. Scan size
100*100nm, scan rate 2frames/sec.
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